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Human pyruvate kinase performs the last step in glucose glycolysis in all cells and 
organisms and can be a key regulator of glycolytic flux. Pyruvate produced by PYK is 
transported into the mitochondria to fuel the TCA cycle, which enables the production 
of ATP; the main energy source of the cell. Human PYK contains four isoforms: M1 
(found in muscle, heart and brain), M2 (in foetal cells and tumours), L (liver), and R 
(red blood cells) PYK. M2PYK plays a crucial role in tumour cell proliferation; by 
down-regulating metabolic flux, upstream metabolites can be used for protein and 
DNA synthesis. Reprogramming the metabolism of fast proliferating cells is called the 
‘Warburg effect’. The biological relevance of the different isoform activities is also 
discussed. For exampleRPYK in red blood cells is exposed to slowly altering 
metabolite concentrations, especially after intestinal absorption in plasma and RBCs 
uptake some of the metabolites. 
This thesis describes biochemical and biophysical studies of human M1PYK, M2PYK, 
LPYK, and RPYK. PYK is allosterically regulated by a range of metabolites. A 
comparative enzyme kinetics study of the four isoforms was performed to examine the 
mechanisms of activation and inhibition of these small molecule regulators, including 
all 20 amino acids and the thyroid hormone T3. The redox state of the environment 
was also found to be an important regulator of PYK activity. All four PYK isoforms 
were successfully expressed and purified. Interestingly, only M2PYK and RPYK were 
strongly regulated by amino acids and metabolites. We also found that the redox state 
regulates the activity of all four PYK isoforms as well as the sensitivity of M2PYK in 
response to natural regulators. These studies also confirmed the dissociation of 
tetrameric PYK into inactive monomers as an important mechanism of regulation, 
particularly for M2PYK activity. Nuclear magnetic resonance (NMR) and Small-angle 
X-ray scattering (SAXS) studies were performed to investigate the conformational 
behaviour of PYK isoforms in solution and to compare the effects of ligand binding. 
NMR data of all four isoforms reveal a conserved binding mechanism between 
isoforms and specific amino acids. SAXS data of all four isoforms demonstrate that 




In each human cell, pyruvate kinase catalyses the last step of glycolytic pathway. Many 
diseases and cell functions correlate with the activity of pyruvate kinase. For example, 
in fast proliferating cells like cancer cells the regulation of pyruvate kinase may be 
involved in the metabolic flux from energy production to amino acids, lipid, 
nucleotides biosynthesis. Some natural effectors have been identified to regulate the 
enzyme allosterically including amino acids and other metabolites. 
It is, therefore, important to further study the interaction between those metabolites 
and human pyruvate kinases. We screened four human pyruvate kinases with 
metabolites including amino acids using a combination of biochemical and biophysical 
assays and revealed that there is a universal binding between human pyruvate kinases 
and amino acids but only some of them act as up- or down- enzymatic regulators. We 
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CHAPTER 1. Introduction 
1.1 Pyruvate kinase is an important enzyme in glycolysis pathway 
1.1.1 The role of pyruvate kinase in cellular metabolism, flux control and gene 
regulation 
Glycolysis converts one molecule of glucose into two molecules of pyruvate and 
releases two ATP (Adenosine triphosphate). Despite the level of free energy released, 
the intermediates are also directly useful in other metabolic pathways, including 
pentose phosphate pathway (the parallel pathway), TCA cycle (the following energy 
releasing reactions), amino acids synthesis, fatty acids synthesis, etc. 
As shown in Figure 1-1, Pyruvate kinase catalyses the last step in the glycolytic 
pathway and converts phosphoenolpyruvate to pyruvate while phosphorylating 
adenosine diphosphate (ADP) to adenosine triphosphate (ATP) (Chaneton & Gottlieb, 
2012; Mazurek, 2011). The reaction is important in the control of the lower part of the 
whole glycolysis pathway. Its substrate PEP (phosphoenolpyruvate) and the product 
pyruvate are both crucial in a variety of metabolic pathways. Pyruvate feeds into the 
TCA (the tricarboxylic acid) cycle in mitochondria (for most eukaryotes)releasing 
more free energy in the form of NADH (Nicotinamide adenine dinucleotide). Cells 
then use another metabolic pathway, oxidative phosphorylation, to generate more ATP. 
In terms of amino acid synthesis, the α-ketoglutarate family of amino acid synthesis 
(glutamate, glutamine, proline and arginine) and the oxaloacetate/aspartate family 
(lysine, asparagine, methionine, threonine, and isoleucine) are derived from TCA 
cycle intermediates α-ketoglutarate and oxaloacetate. The aromatic amino acids 
(phenylalanine, tyrosine, and tryptophan) are synthesized from PEP and Erythrose 4-
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phosphate, which are intermediates from the pentose phosphate pathway. Another 
pentose phosphate pathway middle metabolite, ribose 5-phosphate, leads to histidine 
synthesis, while the Pentose phosphate pathway leads to nucleotide biosynthesis. 
Serine is produced from 3-phosphoglycerate and then it is modified to generate 
cysteine and glycine. In human cells, nine amino acids (phenylalanine, valine, 
threonine, tryptophan, methionine, leucine, isoleucine, lysine, and histidine) cannot be 
synthesized as there are mutated enzymes in the pathway. The ten enzymes of the 





Figure 1-1. Glycolysis pathway from glucose to pyruvate consumes 2 ATP and 
produces 4 ATP for each glucose molecule. Pyruvate feeds into TCA cycle to release 
35 
more energy. The pentose phosphate pathway is shown in grey. All the amino acids 
are shown in blue.   
 
1.1.2 Four PYK isoforms in human cells 
Pyruvate kinases in mammalian tissues were first identified as two types in research 
from the mid 1960’s (Tanaka, Harano, Morimura, & Mori, 1965). There were two 
major types of pyruvate kinases identified from rabbit tissues, L type and M type. Type 
M was isolated from muscle, heart, liver, brain, kidney, fat pads, and leucocytes while 
type L was only found in liver and erythrocytes. In 1987, cDNA clones of rat pyruvate 
kinases L type and R type were isolated (Noguchi, Yamada, Inoue, Matsuda, & Tanaka, 
1987) and in this work it was found that L type PYK and R type PYK are produced 
from a single gene PKLR by splicing with tissue-specific promoters, resulting in exon 
1 in RPYK and exon 2 in LPYK, as shown in Figure 1-2. 
In 1986, it was reported that M1PYK and M2PYK are also made from the same gene 
by alternative RNA splicing (Noguchi, Inoue, & Tanaka, 1986). The alternative 
splicing of PYKM was regulated by heterogeneous nuclear ribonucleoproteins 
(hnRNPs) A1 and A2 and polypyrimidine-tract binding (PTB) protein. M1PYK and 
M2PYK generation depends on the inclusion of exon 9 or exon 10 respectively, as 




Figure 1-2. Upper figure: Alternative splicing of M1PYK and M2PYK by splicing 
factors PTB, hnRNPA2, hnRNPA1 and SRSF3. M1PYK contains exon 9 and 
M2PYK contains exon 10. The picture is from William J’s article (Israelsen & 
Vander Heiden, 2015). Bottom figure: L type PYK and R type PYK are produced 
from a single gene PKLR by splicing with tissue-specific promoters. 
 
The comparison of four human PYK sequences are shown in Table 1. The sequence 
identity between LPYK and RPYK is 94.3%, and sequence identity between M1PYK 
and M2PYK is 95.9%. 
 
 
 Table 1. Sequence identity of human pyruvate kinase isoforms. The pairwise 
sequence identities are calculated with EMBOSS Needle.  
 
1.1.3 Protein structure of M1PYK and M2PYK 
Human pyruvate kinase is a tetrameric enzyme with identical subunits. The 
architecture of human pyruvate kinase M2 is shown in Figure 1-3. M2PYK is a 
homotetramer with each of the four chains comprising an A-domain, B-domain, C-
domain, and a small N-terminal domain. The A domain is the largest domain and forms 
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the main body of the monomer with the B domain and C domain at the sides. The 
active site is located at a cleft between A domain and B domain. The B domain is 
flexible, and it covers on the A domain when the substrate complex (ADP and Mg2+) 
binds to the enzyme  (Larsen, Laughlin, Holden, Rayment, & Reed, 1994). The C 
domain is on the other side and binds the natural allosteric activator FBP. When the 
protein is fully assembled as a tetramer, the C domain forms the C-C interface. The 
spliced exon that is alternatively expressed in M1PYK and M2PYK is located in the 
C domain as shown in bottom picture coloured magenta (Jurica et al., 1998). It shows 
that M2PYK specific exon 10 forms major part of the C-C interface and part of the F-





Figure 1-3. Upper left: the ribbon structure of monomer M2PYK is shown, with the 
A, B, and C domains are depicted in green, magenta, cyan, and N-terminal in 
yellow green, respectively. A group of molecules of K+, Mg2+ and oxalate (a 
PEP analogue) binds to the active site, shown as black spheres. Similarly, FPB 
binds to the effector pocket. Upper right: tetrameric M2PYK (PDB 3BJF, 
(Christofk, Vander Heiden, Wu, Asara, & Cantley, 2008)). The activator side 
for F-1,6-BP and amino acids binding site are indicated. Bottom: the ribbon 
structure of tetramer M2PYK with exon 10 shown as magenta.  
 
The sequence alignment of human pyruvate kinases is show in Figure 1-4. Sequence 
length of wild types of M1PYK, M2PYK, RPYK, LPYK are 531, 531, 574, and 543. 
The F-1,6-BP binding site related residues are indicated in red. Similarities of residue 
between isoforms are indicated by symbols. All isoforms have resolved structures 
available in PDB (RCSB Protein Data Bank), wild type for M1PYK, M2PYK, point 
mutant for LPYK, and truncated mutant for RPYK.  The N-terminal tail of RPYK 
(indicated as strikethrough) was truncated in this structure (Giovanna Valentini et al., 





hsPYK_R    1 MSIQENISSLQLRSWVSKSQRDLAKSILIGAPGGPAGYLRRASVAQLTQELGTAFFQQQQ 60 
hsPYK_L    1 -------------------------------MEGPAGYLRRASVAQLTQELGTAFFQQQQ 29 
hsPYK_M1   1 -------------------------------------------MSKPHSEAGTAFIQTQQ 17 
hsPYK_M2   1 -------------------------------------------MSKPHSEAGTAFIQTQQ 17 
                                                        :::  .* ****:* ** 
 
hsPYK_R  61 LPAAMADTFLEHLCLLDIDSEPVAARSTSIIATIGPASRSVERLKEMIKAGMNIARLNFS 120 
hsPYK_L  30 LPAAMADTFLEHLCLLDIDSEPVAARSTSIIATIGPASRSVERLKEMIKAGMNIARLNFS  89 
hsPYK_M1 18 LHAAMADTFLEHMCRLDIDSPPITARNTGIICTIGPASRSVETLKEMIKSGMNVARLNFS  77 
hsPYK_M2 18 LHAAMADTFLEHMCRLDIDSPPITARNTGIICTIGPASRSVETLKEMIKSGMNVARLNFS  77 
            * **********:* ***** *::**.*.**.********** ******:***:****** 
 
hsPYK_R 121 HGSHEYHAESIANVREAVESFAGSPLSYRPVAIALDTKGPEIRTGILQGGPESEVELVKG 180 
hsPYK_L  90 HGSHEYHAESIANVREAVESFAGSPLSYRPVAIALDTKGPEIRTGILQGGPESEVELVKG 149 
hsPYK_M1 78 HGTHEYHAETIKNVRTATESFASDPILYRPVAVALDTKGPEIRTGLIKGSGTAEVELKKG 137 
hsPYK_M2 78 HGTHEYHAETIKNVRTATESFASDPILYRPVAVALDTKGPEIRTGLIKGSGTAEVELKKG 137 
            **:******:* *** *.****..*: *****:************:::*.  :**** ** 
 
hsPYK_R 181 SQVLVTVDPAFRTRGNANTVWVDYPNIVRVVPVGGRIYIDDGLISLVVQKIGPEGLVTQV 240 
hsPYK_L 150 SQVLVTVDPAFRTRGNANTVWVDYPNIVRVVPVGGRIYIDDGLISLVVQKIGPEGLVTQV 209 
hsPYK_M1138 ATLKITLDNAYMEKCDENILWLDYKNICKVVEVGSKIYVDDGLISLQVKQKGADFLVTEV 197 
hsPYK_M2138 ATLKITLDNAYMEKCDENILWLDYKNICKVVEVGSKIYVDDGLISLQVKQKGADFLVTEV 197 
            : : :*:* *:  : : * :*:** ** :** **.:**:******* *:: * : ***:* 
 
hsPYK_R 241 ENGGVLGSRKGVNLPGAQVDLPGLSEQDVRDLRFGVEHGVDIVFASFVRKASDVAAVRAA 300 
hsPYK_L 210 ENGGVLGSRKGVNLPGAQVDLPGLSEQDVRDLRFGVEHGVDIVFASFVRKASDVAAVRAA 269 
hsPYK_M1198 ENGGSLGSKKGVNLPGAAVDLPAVSEKDIQDLKFGVEQDVDMVFASFIRKASDVHEVRKV 257 
hsPYK_M2198 ENGGSLGSKKGVNLPGAAVDLPAVSEKDIQDLKFGVEQDVDMVFASFIRKASDVHEVRKV 257 
            **** ***:******** ****.:**:*::**:****: **:*****:******  ** . 
 
hsPYK_R 301 LGPEGHGIKIISKIENHEGVKRFDEILEVSDGIMVARGDLGIEIPAEKVFLAQKMMIGRC 360 
hsPYK_L 270 LGPEGHGIKIISKIENHEGVKRFDEILEVSDGIMVARGDLGIEIPAEKVFLAQKMMIGRC 329 
hsPYK_M1258 LGEKGKNIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMMIGRC 317 
hsPYK_M2258 LGEKGKNIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMMIGRC 317 
            ** :*: *************:*******.******************************* 
 
hsPYK_R 361 NLAGKPVVCATQMLESMITKPRPTRAETSDVANAVLDGADCIMLSGETAKGNFPVEAVKM 420 
hsPYK_L 330 NLAGKPVVCATQMLESMITKPRPTRAETSDVANAVLDGADCIMLSGETAKGNFPVEAVKM 389 
hsPYK_M1318 NRAGKPVICATQMLESMIKKPRPTRAEGSDVANAVLDGADCIMLSGETAKGDYPLEAVRM 377 
hsPYK_M2318 NRAGKPVICATQMLESMIKKPRPTRAEGSDVANAVLDGADCIMLSGETAKGDYPLEAVRM 377 
            * *****:**********.******** ***********************::*:***:* 
                    ^                               ^ 
hsPYK_R 421 QHAIAREAEAAVYHRQLFEELRRAAPLSRDPTEVTAIGAVEAAFKCCAAAIIVLTTTGRS 480 
hsPYK_L 390 QHAIAREAEAAVYHRQLFEELRRAAPLSRDPTEVTAIGAVEAAFKCCAAAIIVLTTTGRS 449 
hsPYK_M1378 QHLIAREAEAAMFHRKLFEELVRASSHSTDLMEAMAMGSVEASYKCLAAALIVLTESGRS 437 
hsPYK_M2378 QHLIAREAEAAIYHLQLFEELRRLAPITSDPTEATAVGAVEASFKCCSGAIIVLTKSGRS 437 
            ** ********::* :***** * :  : *  *. *:*:***::** :.*:**** :*** 
 
hsPYK_R 481 AQLLSRYRPRAAVIAVTRSAQAARQVHLCRGVFPLLYREPPEAIWADDVDRRVQFGIESG 540 
hsPYK_L 450 AQLLSRYRPRAAVIAVTRSAQAARQVHLCRGVFPLLYREPPEAIWADDVDRRVQFGIESG 509 
hsPYK_M1438 AHQVARYRPRAPIIAVTRNPQTARQAHLYRGIFPVLCKDPVQEAWAEDVDLRVNFAMNVG 497 
hsPYK_M2438 AHQVARYRPRAPIIAVTRNPQTARQAHLYRGIFPVLCKDPVQEAWAEDVDLRVNFAMNVG 497 
            *: ::****** :*****. *:***.** **:**:* ::* :  **:*** **:*.:: * 
  
hsPYK_R  541 KLRGFLRVGDLVIVVTGWRPGSGYTNIMRVLSIS 574 
hsPYK_L  510 KLRGFLRVGDLVIVVTGWRPGSGYTNIMRVLSIS 543 
hsPYK_M1 498 KARGFFKKGDVVIVLTGWRPGSGFTNTMRVVPVP 531 
hsPYK_M2 498 KARGFFKKGDVVIVLTGWRPGSGFTNTMRVVPVP 531 
             * ***:: **:***:********:** ***: :  
 
Figure 1-4. Sequence alignment of human pyruvate kinase isoforms ((PKM Uniprot 
No.: P14618; PKLR Uniprot No.: P30613).). Identical residues, strongly similar 
residues, and weakly similar residues are indicated by symbols as “*”, “:”, “.” 
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respectively. Residues in the F-1,6-BP binding pocket are indicated as red; residues 
involved in the amino acid binding pocket are indicated in yellow; residues involved 
in the active site are indicated in white. Cysteine 358 and Cysteine 326 on M2PYK is 
indicated by a red colour and bolded. The colour scheme is the same as figure 1-3, A 
domain (residues 25-116), B domain (residues 117-219), and C domain (residues 
403-531) are depicted in green, magenta, cyan, and N-terminal (residues 1-24) in 
yellow green, respectively. 
 
 
1.1.4 M2PYK regulation on gene expression level in cancer cells 
In 1927, Otto Warburg observed the metabolic difference between normal 
differentiated cells and cancer cells (Warburg, Wind, & Negelein, 1927). Cancer cells 
utilize the aerobic glycolysis pathway which is a relatively less efficient way to 
produce ATP (adenosine 5’-triphosphate) compared with the mitochondrial oxidative 
phosphorylation (Heiden, Cantley, & Thompson, 2009). The Warburg effect argued 
that cancer cells lose their cellular respiratory capacity. But Crabtree suggested that 
some tumours have high respiration rates (Crabtree, 1929). 1980, Eigenbrodt 
demonstrated that on one hand, M2PYK was phosphorylated and inactivated by 
protein kinases showing that the enzyme is related to cancer signalling; on the other 
hand, M2PYK enzymatic activity inhibition step is important in nucleotide 
biosynthesis, showing that the enzyme is connected to cancer metabolism  (Eigenbrodt, 
Reinacher, Scheefers-Borchel, Scheefers, & Friis, 1992; Mazurek, 2011).  
The expression of M2PYK is regulated at multiple levels including DNA methylation, 
transcription factors, pre-mRNA slicing of PKM gene, PKM2-specific microRNAs 
and post-translational modifications of the PKM2 proteins (Israelsen & Vander Heiden, 
2015). One important mechanism was revealed indicating that epigenetic regulation 
by DNA methylation was found in PKM transcription across multiple cancers (Desai 
et al., 2013). Several transcriptional factors were found to regulate the promotor 
activity of PKM (Discher, Bishopric, Wu, Peterson, & Webster, 1998; Yamada, 
Tanaka, Miyamoto, & Noguchi, 2000; Yang & Lu, 2013). At the transcription level, 
activity can be upregulated by oncogenic transcription factors. Heterogeneous nuclear 
ribonucleoproteins (hnRNPs) bind to splicing signals that flank PKM exon 9 and then 
upregulate M2PYK expression (David et al., 2010). miRNA, which function by 
specifically binding to target mRNAs to hinder the translation, was also found to 
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regulate expression of M2PYK. Activity was reduced by PKM transcript targeted 
miRNA to overexpressed M2PYK (Wong et al., 2008) or by targeting the splicing 
factors PTB, hnRNPs to switch the gene expression from M1PYK to M2PYK, 
consequently leading to lower cancer cell growth (Sun, Zhao, Zhou, & Hu, 2012). 
Finally, the acetylation of M2PYK also provides a regulation route to degrade the 
enzyme, which in turn promotes cell proliferation and tumorigenesis (Lv et al., 2011). 
Further evidence also indicates that expression of M2PYK is not necessary for growth 
of some human tumour cell lines in mice, including liver tumours, leukaemia, 
xenograft tumours or breast tumours (Dayton et al., 2016; Israelsen & Vander Heiden, 
2015). Although the loss of M2PYK leads to cancer growth in some tumours and 
activation of M2PYK can impair some tumour growth, in some reports M2PYK is not 
viewed as a good therapeutic target in many cancers, which are able to tolerate loss of 
pyruvate kinase expression (Israelsen & Vander Heiden, 2015).  
1.1.5 Regulation of the enzymatic activity and metabolic functions of M2PYK 
M2PYK activity can be regulated by glycolytic intermediates. Fructose 1,6-
bisphosphate (F-1,6-BP) activates the protein by improving its tetramerization, as the 
dimers and monomers have very low activities (Christofk et al., 2008). The 
phosphorylated tyrosine binding leads to a reverse effect by disruption of 
tetramerization. Human M2PYK mutants H391Y and K422R found in Bloom 
syndrome patients shows that these missense mutations reduce M2PYK activity. The 
reduction subsequently leads to accumulation of glycolytic intermediates, cell 
proliferation, polyploidy and tumour growth (Gupta & Bamezai, 2010; Iqbal et al., 
2013). Deactivated M2PYK was reported to result in PEP-dependent histidine 
phosphorylation and activation of phosphoglycerate mutase, which catalyse the 8th step 
of glycolysis, as well as less ATP production. This means that deactivated M2PYK in 
cancer cells promotes aerobic glycolysis with increased glucose consumption and 
contribute to anabolic metabolism (Vander Heiden, Locasale, et al., 2010). 
Furthermore, gene knockout experiment showed that absence of M2PYK in primary 
mouse embryonic fibroblasts results in reduced DNA synthesis level and impaired cell 
cycle progress. M2PYK is crucial for normal cell proliferation (Lunt et al., 2015). 
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Serine was found to be another allosteric activator of M2PYK (Chaneton et al., 2012). 
When serine is sufficient, M2PYK is fully activated, allowing a high glycolytic rate to 
consume glucose. When serine is not abundant, M2PYK is deactivated, leading to 
carbon flux to serine biosynthesis (Chaneton et al., 2012). Another intermediate 
succinyl-5-aminoimidazole-4-carboxamide-1-ribose-59-phosphate (SAICAR) is 
another allosteric regulator. It activates M2PYK to raise glucose consumption rates 
(Keller, Tan, & Lee, 2012).  
M2PYK can also be regulated by post-translational modifications including 
phosphorylation. Phosphorylation on Y105 deactivated M2PYK by promoting 
dimerization of the enzyme, this was shown to result in cell proliferation and 
tumorigenesis (Hitosugi et al., 2009). Oxidation on C358, induced by ROS (reactive 
oxygen species), diamide (a thiol-oxidizing compound) or hypoxia deactivates 
M2PYK, leading to diversion of glucose flux into the pentose phosphate pathway to 
generate a reducing potential to balance the oxidative environment and cell 
proliferation (Anastasiou et al., 2011). 
1.1.6 Hyperglycaemia and LPYK as drug target 
Allosteric activators of LPYK have been identified through high-throughput screening 
as a potential therapy for hyperglycaemia. The mechanism is to activate LPYK enzyme 
activity to create a glycolytic/gluconeogenic futile cycle (Fenton, 2012). The 
activation of the drug target enzyme LPYK is to increase the glycolysis pathway 
efficiency and consuming more glucose to counteract hyperglycaemia. 
1.1.7 Erythrocyte pyruvate kinase (RPYK) deficiency 
Pyruvate kinase deficiency is caused by the PKLR gene mutations or genetic variations  
(Fermo et al., 2005). As the glycolysis pathway is the only energy source in RBC (red 
blood cell), decreased enzyme activity leads to anaemia (van Zwieten et al., 2015). In 
literature, people affected by pyruvate kinase mutations are estimated at 1 in 20,000 
and more than 158 mutations of PKLR gene have been identified (Zanella & Bianchi, 
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2000). However, pyruvate kinase deficiency is a protective effect in against malaria as 
it prevents the parasites  replicating in red blood cells (Ayi et al., 2008). 
1.2 Natural regulation of human PYKs 
1.2.1 Allosteric effects 
In 1903, haemoglobin research by C. Bohr revealed that ligand binding of a multimeric 
protein could lead to affinity changes of another ligand. The phenomenon is called 
cooperativity, which could be either homotropic, where the binding affinity of one 
ligand is changed by the binding of a same ligand, or heterotropic, where the binding 
affinity of one molecule is changed by the binding of a different molecule on the 
polymeric protein. In 1965, the MWC (Monod-Wyman-Changeux) allosteric model 
was conceived to explain cooperativity of such allosteric effects in homo-tetrameric 
complexes (Monod, Wyman, & Changeux, 1965). The phenomenon explains that 
equilibrium of tensed (T state) and relaxed (R state) protein depends on the binding of 
a ligand to an allosteric site. All four units of a tetrameric protein are in same state at 
any time, there are two pre-existing quaternary states (T state and R state) (Changeux, 
2012). That is to say the binding of the substrate to one subunit alters the affinity of all 
other subunits by T-R transition. And the model holds further that when there is no 
ligand binding, the equilibrium favours one of the conformational states. The 
equilibrium can be changed by binding in a pocket different from the active site. In 
this case, the ligand is defined as an allosteric effector and the pocket is the allosteric 
site. In 1966, the Koshland, Nemethy and Filmer (KNF) model suggested that in a 
given tetramer, both R state and T state units exist (Koshland, Nemethy, & Filmer, 
1966). The model is also named the sequential model. The binding of one subunit leads 
to the tertiary T-R transition and any of other subunits can exist in a different state. 
The binding only slightly changes the structure of other subunits so that their binding 
pocket are more receptive to the substrate. 
Pyruvate kinase is an example of allosterically regulated enzyme. This is a conserved 
property of this enzyme with E. coli pyruvate kinase, yeast pyruvate kinase, and human 
M2PYK, all allosterically activated by F-1,6-BP, which is a product of the PFK 
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(phosphofructokinase) reaction (Jurica et al., 1998). F-1,6-BP activates both RPYK 
and LPYK allosterically however M1PYK is regarded as a non-allosteric enzyme and 
shows constitutively full activity (Prasannan, Tang, & Fenton, 2012; G Valentini et al., 
2000). In human cells, M2PYK, LPYK, and RPYK are upregulated by PEP in a 
homotropic cooperative way and by F-1,6-BP in a heterotropic cooperative way 
(Gupta & Bamezai, 2010). PEP is the substrate of PYKs however this is not an 
allosteric effect as it affects the affinity on the same pocket. F-1,6-BP is an allosteric 
effector to PYKs as its binding to the protein leads to higher affinity to substrate 
binding. M2PYK is also allosterically inhibited by the thyroid hormone 3,3',5-triiodo-
L-thyronine (T3). T3 prevents tetramerization and stabilizes monomer M2PYK (Kato, 
Fukuda, Parkison, McPhie, & Cheng, 1989).  
There is growing literature showing that amino acids act as another family of allosteric 
regulators for human PYKs. Published amino acid activators of human pyruvate kinase 
are summarized in Chapter 4.1.1.  Some amino acids are activators and while others 
are inhibitors. Amino acids are as important as F-1,6-BP in the regulation of PYK 
activity and glycolytic flux control. For example, serine as a natural allosteric activator 
of M2PYK and may regulate the serine biosynthesis pathway, which is crucial for 
cancer cell proliferation (Chaneton et al., 2012). It was described as a rheostat-like 
mechanistic system as shown in Figure 1-5. When the overall PYK activity is low via 
the preferential expression of M2PYK, which has low basal enzymatic activity 
compared with M1PYK, the intermediates related to serine biosynthesis accumulate 
including 3PGA (3-phosphoglycerate) and PEP. When serine is abundant, M2PYK is 
fully activated and the carbon flux used through glycolysis as shown in the righthand 
figure in Figure 1-5. However, when the serine concentration drops, the enzymatic 
activity of M2PYK cannot be maintained, the intermediates, 3PGA and PEP, will 
accumulate and the carbon flux is redirected to serine biosynthesis pathway to 
compensate for the shortfall of serine and other related amino acids. 
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Figure 1-5. Illustration of the rheostat-like mechanistic system of serine biosynthesis 
pathway and the M2PYK activity.  
The amino acid binding pockets of human PYKs are conserved as shown in Figure 1-6. 
In the left figure, four structures show almost the same pocket. In the right, the pocket 
of M2PYK (white) co-crystalized with phenylalanine (red) in its pocket.  
 
Figure 1-6. The left figure shows the amino acid pocket area of a series of aligned 
human pyruvate kinase crystal structures. The four structure are Apo enzymes. The 
right figure is the alignment of four isoforms with a M2PYK co-crystalized with 
phenylalanine. The structure of M1PYK (3SRF), M2PYK (4FXJ), LPYK (4IP7) and 
RPYK (2VGB) are coloured in yellow, blue, green, and purple respectively. The 
white structure in the right figure is the M2PYK (4FXF) co-crystalized with 
phenylalanine (red). 
It is highly possible that phenylalanine or other amino acids could bind to these pockets. 
As described in Chapter 4, we screened four human PYK isoforms with a group of 
amino acids. Surprisingly, many other amino acids were found to be regulators of 
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M2PYK and RPYK. Further investigation between the binding of human PYKs and 
amino acids were carried out through STD-NMR, which is shown in Chapter 5. We 
demonstrated that all amino acids we tested bind to any of the four isoforms. These 
results might indicate that the conserved amino acid pockets in PYKs bind to amino 
acids, which are biochemical regulators (some activators and some inhibitors) or non-
regulators. As there is no additional ligand-protein structure evidence generated from 
this research, we don’t know if these very different amino acids (large/small; 
positive/neutral/negative) bind to the same or different pockets.  
A rock and lock Allosteric model of PYK 
In 2010, a study of Leishmania mexicana pyruvate kinase (LmPYK) demonstrated a 
rock and lock allosteric model of PYK (Hugh P. Morgan et al., 2010). LmPYK could 
be stabilized by ATP and oxalate or locked by the effector fructose 2,6-bisphosphate 
(F-2,6-BP) through rigid body rotation of each unit of the protein. 
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Figure 1-7. The schematic diagram of LmPYK allosteric mechanism: a, 
representation of inactive T-state, the relative positions of effector and substrate are 
shown; b, binding of ATP and oxalate to the active R-state of LmPYK; c, active R-
state LmPYK binding with ATP, oxalate and F-2,6-BP; d, active R-state locked by 
F-2,6-BP; e, superposition of inactive T-state and active R-state. The figure is from 
the study from Morgan’s article. 
1.2.2 Hormonal control on human PYKs 
It has been studied that both known dietary and hormonal regulators of LPYK alter the 
glycolysis pathway by controlling LPYK at the mRNA level. Glycogen and cyclic 
AMP (adenosine monophosphate) inhibit the induction of LPYK mRNA. The 
presence of insulin and dietary carbohydrates activate the mRNA synthesis of LPYK 
(Munnich et al., 1984; Vaulont, Munnich, Decaux, & Kahn, 1986). Recently research 
has shown that insulin plays a very important role in the regulation of M2PYK in 
cancer cells by up-regulation of M2PYK expression but significantly reducing its 
activity (Iqbal et al., 2013). In this process, glycolytic flux is diverted to biosynthesis 
and cell growth by insulin. 
Thyroid hormone also inhibits LPYK at the transcription level (Munnich et al., 1984). 
The structures of thyroid hormone T3 (triiodothyronine) and its prohormone T4 




Figure 1-8. The structural formula of thyroid hormone. The upper figure is 
triiodothyronine (T3), the bottom figure is thyroxine (T4). 
It was reported that when red blood cells are incubated with thyroid hormone, the level 
of 2,3-BPG (2,3-bisphosphoglyceric acid increases) (Snyder & Reddy, 1970). In 1967, 
Reinhold and Ruth Benesch found that in red blood cells, 2,3-BPG acts as an allosteric 
effector of haemoglobin to decrease its affinity of oxygen (Benesch & Benesch, 1967). 
In addition, it was also found that in the blood of hyperthyroid patient, 2,3-BPG level 
increased (Zaroulis, Kourides, & Valeri, 1978). The haemoglobin saturation curve is 
shown in Figure 1-9. 2,3-BPG is a major regulator of the haemoglobin-oxygen affinity. 
Left and right shifts of the curve represent higher and lower oxygen affinity. But how 
thyroid hormone affects the 2,3-BPG production is still unclear. 
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Figure 1-9. The haemoglobin saturation curve of how pH, temperature, and 2,3-BPG 
(shown as DPG in the figure) affect the affinity of oxygen with haemoglobin. X-axis 
is the partial pressure of oxygen and y-axis is the oxygen saturation by percentage. 
When pH goes up, or 2,3-BPG levels decrease, or the temperature goes down, the 
saturation curve moves to left (blue curve to green one). When these conditions 
change to the other direction, the curve moves to right (from blue to red). 
Interestingly, in our research both thyroid hormone T3 and T4 inhibit RPYK, which is 
discussed in Chapter 4. It is highly possible that the activity of RPYK in red blood 
cells is inhibited by increasing thyroid hormone level. Then one of the middle products 
from the glycolysis pathway as shown in Figure 1-1, 1,3-BPG (1,3-bisphosphoglyceric 
acid), is accumulated in red blood cells. Bisphosphoglycerate mutase transform 1,3-
BPG to 2,3-BPG (2,3-diphosphoglyceric acid). As the Luebering-Rapoport pathway 
described shown in Figure 1-10, bisphosphoglycerate mutase catalyzes the transfer of 
a phosphoryl group from C1 to C2 of 1,3-BPG, forming 2,3-BPG. Then, 
bisphosphoglycerate phosphatase catalyses the reaction from 2,3-BPG to 3-
phosphoglycerate. When RPYK is inactivated, upstream intermediates accumulate. 
The hypothesis is that thyroid hormones regulate RPYK to control the 2,3-BPG 
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concentration in red blood cells and control the oxygen affinity of haemoglobins. The 
schematic diagram is shown in Error! Reference source not found.. 
 
Figure 1-10. The schematic diagram of the hypothesis that thyroid hormones (T3/T4) 
regulate the affinity of oxygen with haemoglobin (Hgb). RPYK activity is down-
regulated by T3/T4 and the glycolysis pathway is altered to accumulate intermediate 
1,3-BPG. Then, 1,3-BPG is catalysed by Bisphosphoglycerate mutase (BPGM) to 
2,3-BPG, which in turn allosterically regulates the oxygen affinity of Hgb. Black 
arrows show the energy production direction of the glycolysis pathway. Purple 
arrows show the hypothesised T3/T4 regulation pathway. 
Other research has reported that hyperthyroidism can affect hepatic system and even 
cause up to 65% hepatic dysfunction (KHEMICHIAN, 2001). Research in Graves’ 
hyperthyroidism also indicates that people with this disease are often observed to 
suffer hepatic dysfunction (Wang, Tan, Zhang, Zheng, & Li, 2017). The effect of T3 
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and T4 on LPYK has been tested and shown in Chapter 4. Both thyroid hormones are 
strong inhibitors for LPYK.  It is also possible that excessive thyroid hormone 
secretion increases the T3/T4 concentration in hepatocytes and inhibition of LPYK by 
thyroid hormones may lead to poor efficiency of energy production. Our hypothesis is 
that the regulation of thyroid hormone on LPYK may play an important role in this 
type of hepatic dysfunction. 
1.3 The biochemical environment of human PYKs 
In this thesis, we discuss two aspects of the biochemical environment of human PYKs: 
redox environment and free amino acids concentration. Neither are homogeneous in 
human tissues and will also vary depending on physical stress affecting the body.  For 
example, redox status and regulation is different between normal cells and cancer cells 
(Gaascht et al., 2014). Free amino acid concentration changes after a high-protein meal 
(FRAME, 1958) or exercise (McCormack, Cooke, O’Connor, & Jakeman, 2017). 
Nutrient availability is also different in various tissues (Canepa et al., 2002). Human 
PYK isoforms are expressed in various human tissues and work in very different 
environments, especially RPYK, which is travelling in the human body within red 
blood cells through all kinds of tissues. It is therefore of interest to test how redox 
reagents and amino acids regulate human pyruvate kinases. Results from such studies 
are recorded in Chapter 3 and 4. 
1.3.1 ROS regulation on M2PYK 
Redox, short for reduction and oxidation reactions, is often described as the balance of 
several chemical pairs, GSH (Glutathione) /GSSG (Glutathione disulfide), NAD+ 
(oxidized nicotinamide adenine dinucleotide) /NADH (reduced nicotinamide adenine 
dinucleotide) and NADP+ (nicotinamide adenine dinucleotide phosphate) /NADPH 
(reduced nicotinamide adenine dinucleotide phosphate).  
In lung cells, ROS (reactive oxygen species) regulation of M2PYK is crucial for 
detoxification of ROS. When intracellular ROS concentration increases and oxidative 
stress builds up, Cys358 on M2PYK is oxidized and the metabolic flux changes to the 
pentose phosphate pathway, this generates enough reducing reagents to detoxify the 
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oxidized environment (Anastasiou et al., 2011). Not only human PYK but also its 
orthologues in other species, from bacteria to mammalian cells, can be inhibited by 
ROS (Butterfield & Sultana, 2007; Cumming et al., 2004; Maeba & Sanwal, 1968). A 
study in this area suggested that ROS contributes to the development of the severe 
disease Pulmonary Arterial Hypertension by decreasing M2PYK activity. Activators 
of M2PYK might be a potential treatment for this disease (D. Guo et al., 2016).  
1.3.2 Amino acid regulation in cancer cells 
Amino acids are building blocks in protein synthesis but they are also important 
signalling and regulatory metabolites in a number of cellular pathways. Fast 
proliferation in tumours require cancer cells to alter their metabolic flux to increase 
biomass production (Hanahan & Weinberg, 2011). Cancer metabolism has been 
heavily explored, some drug development programmes target glycolysis and oxidative 
phosphorylation. A metabolic starvation therapy removing or limiting the availability 
of some metabolites including amino acids was studied (Changou et al., 2014). It was 
thought this might be a more efficacious method as it is less toxic than chemotherapy 
or radiation. In these programmes, nonessential amino acids are important as potential 
starvation inducing metabolites. Normally they can be synthesized in cells but some 
nonessential amino acids become essential in cancer cells due to their altered 
metabolism, as demonstrated in breast cancer cells (Geck & Toker, 2016). The amino 
acid concentration in saliva from patients with breast cancer was shown to be changed 
significantly compared with healthy controls (Cheng, Wang, Huang, Duan, & Wang, 
2015).  
Of all amino acids, glutamine is the most consumed amino acid in cancer cells (Jain et 
al., 2012). Although consumed in nucleotide and lipid biosynthesis, glutamate is 
produced from glutamine via glutaminolysis, which is often increased in cancer cells 
(Erickson & Cerione, 2010). Apart from glucose, glutamine (as the most abundant 
amino acid in the bloodstream) plays one of the most important roles as building blocks 
for growth by two processes: glycolysis and glutamine utilization by reductive 
carboxylation. All other NEAAs (non-essential amino acids), including serine, glycine, 
cysteine, tyrosine, alanine, aspartic acid, asparagine, arginine, proline, are derived 
from glutamine utilization in cancer cells (Alberghina & Gaglio, 2014; Thiele et al., 
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2013). A schematic representation is shown in Figure 1-11 A. Some amino acids, about 
50% of the amino acids required for protein synthetic activity of cancer cells, are 
derived from glycolysis pathway intermediates: serine, glycine and cysteine derived 
from 3PGA (3-Phosphoglycerate); tyrosine from PEP; alanine from pyruvate (Pyr in 
the figure). While the other 50% of the required amino acids in cancer metabolism 
rewiring, including asparagine, arginine, proline, aspartic acid, are derived from 
glutamine metabolism. 
The metabolic pathways have been rewired to support biosynthesis of proteins, 
nucleotides, glycans, and lipids, as well as production of energy and NADPH. A 
concept map from Alberghina’s article is shown in Figure 1-11 B (Alberghina & 
Gaglio, 2014) . Glycolysis is identified as yellow arrows. Glutamine metabolism is 
represented by blue arrows. Pentose phosphate pathway is shown in green arrows. 
Bright lilac arrows are the pathway of serine/glycine and folate metabolism. The red 
arrows identify an NAD(P)H electron transfer flux (ETF). Both glutamine and glucose 
are transferred within cancer cells to support the altered metabolism. Glycolysis 
pathway provides free energy to support the energetics in cancer cells; provides the 
carbon skeleton to half of amino acid biosynthesis; provides 3PGA to fuel serine 
biosynthesis pathway. Pentose phosphate pathway provides NADPH to support amino 
acids biosynthesis, lipid biosynthesis, and redox balance. Glutamine metabolism 
pathway supplies α-ketoglutarate to fuel TCA cycle and TCA cycle produces 





Figure 1-11. A: NEAA biosynthesis pathways. B: Concept map of the cancer 
metabolic rewiring. Abbreviations: 1,3BPGA, 1,3-bisphosphoglycerate; 3PGA, 3-
phosphoglycerate; 6PGL, 6-phosphogluconolactone; AcCoA, acetyl-CoA; ACL, 
ATP citrate lyase; Akg, α-ketoglutarate; Ala, alanine; Arg, arginine; Asn, asparagine; 
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Asp, aspartate; CH+-Thf, 5-methylenetetrahydrofolate; CH2-Thf, 5,10-
methylenetetrahydrofolate; Cit, citrate; Cys, cysteine; F-1,6-BP, fructose 1,6 
bisphosphate; FFA, fatty acids; G6P, glucose 6-phosphate; GA3P, glyceraldehyde 3-
phosphate; Glc, glucose; Gln, glutamine; Glu, glutamate; Gly, glycine; GOT, 
glutamic-oxaloacetic transaminase; GSH, glutathione reduced; GSSG, glutathione 
oxidized; Lac, lactate; LDHA, lactate dehydrogenase; MDH 1, malate 
dehydrogenase; ME, malic enzyme; MTHFD1 and 2, methylenetetrahydrofolate 
dehydrogenase (NADP+ dependent); NEAA, non-essential amino acids; Oaa, 
oxaloacetate; PPP, pentose phosphate pathway; P-Pyr, 3-phosphohydroxypyruvate; 
Pyr, pyruvate; R5P, ribose 5-phosphate; ROS, reactive oxygen species; Ser, serine; 
SHMT1 and 2, serine hydroxymethyltransferase 
Glutamine maintains a relatively high concentration to support glutamine metabolism 
as both carbon donor and nitrogen donor, with a combination of sources such as dietary 
uptake, de novo synthesis, and muscle protein catabolism (Zhang, Pavlova, & 
Thompson, 2017). Another important intermediate metabolite amino acid is serine. As 
discussed in Chapter 1.2.1, elevated intracellular serine levels cause feedback of 
M2PYK activation, which leads to serine/glycine biosynthesis(Gravel et al., 2014). 
1.3.3 Amino acid concentration in erythrocytes 
Amino acid concentration has been widely reported to vary in different tissues. Free 
intracellular amino acids are crucial for protein synthesis and they accumulate at the 
site of protein synthesis (Canepa et al., 2002). Skeletal muscles contain most free 
intracellular amino acids (Bergström, Alvestrand, & Fürst, 1990).   
It was reported that erythrocytes play an important amino acids transportation role in 
the process of post-absorptive state in health humans (Agli, Schaefer, Geny, Piquard, 
& Haberey, 1998). In this report, oral load of amino acids was used to investigate 
whether erythrocytes absorb amino acids during the period of intestinal absorption. 
The result showed that for most amino acids erythrocytes contained higher 
concentrations than plasma after an oral load. The amino acids concentration test of an 
oral load experiment lasted 125 minutes and suggested that after a period of 25-50 
minutes, amino acid exchange might take place between plasma and erythrocytes. The 
result from this report is shown below in (Agli et al., 1998). So, RPYK in cytosol of 
erythrocytes are in an environment with changing amino acids concentrations and the 
glycolysis rate might change if these amino acids affect the enzymatic activity of 
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RPYK. This effect might be important as glycolysis is the only pathway in erythrocytes 
to produce ATP. 
 
Figure 1-12. The time dependant variations of the mean amino acid concentrations 
for plasma (o) and erythrocytes (x). The changes in concentration are given by α 
(plasma) and β (erythrocytes). 
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1.4 Formulation of the objectives of the research 
Firstly, we purified proteins and investigated the biophysical, biochemical properties 
of all human pyruvate kinase forms. During the study, we discovered that the activities 
of pyruvate kinases are affected significantly by a couple of experimental operations, 
which are not recorded in other reports in this area, these include the pre-incubation 
time after protein been diluted from stock to the start of the enzymatic reaction and the 
redox environment. It is therefore difficult to compare the enzymatic results from 
different literatures about pyruvate kinases. We verified the experimental methods to 
determine the optimum way to study pyruvate kinase activity and how its activity is 
affected by pre-incubation time, redox environment and the protein concentration itself. 
This provides stable protein activity data and allows the results from different batches 
of protein or sets of experiments to be compared. 
Secondly, the metabolism in proliferating cells is rewired and metabolites including 
glycolysis intermediate products, amino acids, TCA cycle middle products in these 
cells are redirected to feed other energetic or biosynthetic pathways. The 
concentrations of these metabolites is changed, however in this changing environment, 
metabolic regulation of this sensitive enzyme pyruvate kinase M2 involving amino 
acids is not fully understood. It is necessary therefore to study how various amino acids 
regulate M2PYK.  
Thirdly, as the concentrations of amino acids in erythrocyte change after intestinal 
absorption, it will be quite important to investigate how these amino acids specifically 
affect erythrocyte metabolism especially involving reactions with pyruvate kinase R 
type. Pyruvate kinases have been shown to be regulated by amino acids, but the effects 
of amino acids on RPYK activity is still unknown. 
In this study, we screened all amino acids with all four human pyruvate kinases in 
order to investigate the regulations between them.  
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CHAPTER 2. Biophysical, Biochemical and kinetics 
characterization of pyruvate kinase isoforms 
2.1 Gene expression, protein purification 
2.1.1 Expression of His-tagged M1PYK, His-tagged M2PYK, His-tagged LPYK 
and His-tagged RPYK 
All four proteins (His-tagged M1PYK, His-tagged M2PYK, His-tagged LPYK and 
His-tagged RPYK) used in this thesis were expressed in E. coli. The proteins are N-
terminally His6-tagged with a cleavage site (MGSSHHHHHHSSGLVPRGSH). It was 
reported in literatures of using a His-tagged pyruvate kinase in both enzymatic assays 
and crystallization (Chen et al., 2011; Dombrauckas, Santarsiero, & Mesecar, 2005; 
Vander Heiden, Christofk, et al., 2010). The His-tag helps to yield high purity protein 
and didn’t show much influence on enzyme structure and enzymatic activity.  
Transformation step: Chemically competent cells (BL21_DE3 Escherichia. coli 
Novagen) were transformed with plasmids encoding human pyruvate kinases (hPYKs) 
(pET28A_M1PYK, pET28A_M2PYK, pET28A_LPYK or pET28A_RPYK) 
separately. The four recombinant clones were prepared by Dr Hugh Morgan in house 
using GENSCRIT DNA synthesis service. The process of transformation is as follow. 
About 100 ng of each plasmid was added into a tube of 20 µl E. coli cells. The tube 
was incubated on ice for 30 min, then it was treated with heat shock at 42 oC for 45 s. 
The sample was put on ice for another 2-min incubation. Afterwards, 250 µl of 37 oC 
SOC (super optimal broth) was added into each tube. Then, each sample was incubated 
at 37 oC for 60 min in a shaker at 250 rpm. Then, the bacteria in each tube were streaked 
onto agar plates (lysogeny broth with 50 µg/ml kanamycin), which were pre-incubated 
at 37 oC for 10 min. The plates were incubated at 37 oC for 12-16 hours. 
59 
Expression step: Single colonies of transformed cells containing the target gene 
structures were picked from LB (lysogeny-broth) plate (containing 50 µg/ml 
kanamycin) and used to inoculate 50 ml of 2xTY mediacontaining 50 µg/ml 
kanamycinseparately, then incubated 18 hours at 37 oC with agitation. 20 ml of each 
overnight cultures were used to inoculate one litre of 2xTY media containing 50 µg 
per ml kanamycin. Cultures were grown at 37 oC with agitation an OD 600 of 0.8-1.0 
and then incubated in cold room at 4 oC for 40 minutes. 1 mM IPTG (isopropyl-β-D-
thiogalactopyranoside) was added in cultures to induce protein expression. Cultures 
were incubated at 20 oC for 18 hours with shaking. Cells were frozen freshly in liquid 
nitrogen after been harvested at 8,000 rpm for 40 minutes using a JLA-9,1000 rotor at 
10 oC. Cell pellets were weighted and stored at -80 oC. 
Cell culture medium recipes (1 L medium) used in the process are as follow: lysogeny 
broth (10 g Tryptone, 5 g yeast extract, and 10 g NaCl, pH 7.2); lysogeny broth agar 
(15 g agar, 10 g Tryptone, 5 g yeast extract, and 10 g NaCl, pH 7.2); 2x TY (Tryptone 
Yeast) (16 g Tryptone, 10 g yeast extract, and 5 g NaCl, pH 7.4); super optimal broth 
(20 g BactoTM Tryptone, 5 g OxoidTM yeast extract, 0.58 g NaCl, 0.188 g KCl, 2.47 g 
MgSO4, 2.03 g MgCl2, and 3.60 g glucose) 
2.1.2 Preparation of cell lysates for His6-hPYKs 
Cell pellets of the four isoforms were placed on ice to thaw and resuspended in lysis- 
buffer (30 ml buffer/5g cells). Lysis-buffer consists of 50 ml of buffer A (50mM 
NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0) supplemented with one tablet of 
EDTA free protease inhibitors (Roche). A constant disruption system (Constant 
System Disruptor TS Series Benchtop instrument) was used to lyse the resuspended 
19 cells with pressure set to 22 KPSI instrument reading (equivalent to 152 MPa). The 
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cell lysate was centrifuged at 23,000 rpm for 50 min at 10 oC using a JA-25,50 rotor. 
Cellular debris was removed and the supernatant was collected on ice and filtered 
using a 0.2 µm syringe filter. 
2.1.3 Purification of prokaryotic expressed His6-hPYKs 
First step IMAC: All steps were processed at 4 oC. Clarified cell lysates containing 
His6-hPYKs were loaded onto a 5 ml IMAC HiTrap HP Sepharose column (pre-
charged with cobalt and pre-equilibrated with buffer A; column was purchased from 
GE Healthcare) at 2 ml/min. The flow through of the column was maintained at a 
constant rate of 2 ml/min throughout the affinity chromatography step. After the PYK 
samples were loaded, the column was washed with 10 column volumes (CV) of buffer 
A (20 mM imidazole, 50 mM NaH2PO4, 300 mM NaCl, pH8.0) to wash out 
contaminating proteins and change buffer in the column, followed by an additional 
wash step with 15 CVs of 80% buffer A and 20% buffer B (250 mM imidazole, 50 
mM NaH2PO4, 300 mM NaCl, pH 8.0) to wash off non-specific binding proteins. The 
His6-hPYK proteins were eluted using 5 CVs of 100% buffer B. Samples were 
concentrated with Vivaspin® tubes with cut-off molecular mass 30 kDa to 2 ml for 
next step. 
Second step: A Superdex 200 26/60 XK size-exclusion column was pre-equilibrated 
with 5 CVs of PBS-CM (Dulbecco’s phosphate buffered saline without calcium and 
magnesium [Sigma Cat. No. D5652]) and used to load eluted fractions pooled from 
the affinity step at a flow rate of 2.5 ml/min throughout the size-exclusion step. Eluted 
fractions were pooled and concentrated to 10 mg/ml using a Vivaspin® tube with a 
molecular weight cut-off of 30 kDa. The concentrations of the proteins were measured 
using a Nanodrop® 2000 spectrophotometer. The concentration measurement and the 
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protein purity was checked by SDS-PAGE. All proteins were frozen using liquid 
nitrogen and stored at -80 oC. 





Figure 2-1. Upper part: IMAC of M1PYK, the elution of proteins was monitored by 
a UV spectrometer at 280 nm (represented by the solid line) and dashed line shows 
the percentage of Buffer B used for the IMAC purification. Bottom part: gel-
filtration purification of M1PYK and figure of SDS-PAGE, showing the purity of the 
protein, M represents protein marker with unit (kDa). 











































Figure 2-2. Upper part: IMAC of M2PYK, the elution of proteins was monitored by 
a UV spectrometer at 280 nm (represented by the solid line) and dashed line shows 
the percentage of Buffer B used for the IMAC purification. Bottom part: gel-
filtration purification of M2PYK and figure of SDS-PAGE, showing the purity of the 




































































Figure 2-3. Upper part: IMAC of LPYK, the elution of proteins was monitored by a 
UV spectrometer at 280 nm (represented by the solid line) and dashed line shows the 
percentage of Buffer B used for the IMAC purification. Bottom part: gel-filtration 
purification of LPYK and figure of SDS-PAGE, showing the purity of the protein, M 




Figure 2-4. Upper part: IMAC of RPYK, the elution of proteins was monitored by a 
UV spectrometer at 280 nm (represented by the solid line) and dashed line shows the 
percentage of Buffer B used for the IMAC purification. Bottom part: gel-filtration 

























































purification of RPYK and figure of SDS-PAGE, showing the purity of the protein, M 
represents protein marker with unit (kDa).  
 
2.1.4 Measurement of protein concentration 
Protein concentration was determined by measurement of the absorbance at 280nm 
using a Nanodrop spectrophotometer and the Beer-Lambert law: A= ε*c*l (A, 
absorbance; ε, molar absorbance coefficient, l, path length; c, protein concentration). 
The theoretical molar absorption coefficient and molecular weight of PYK isoforms, 
which are estimated by http://web.expasy.org/protparam/, are shown in Error! 
Reference source not found.. Estimated molecule weight His-tagged M2PYK, His-
tagged M1PYK, His-tagged LPYK and His-tagged RPYK of 60.1 kDa, 60.2 kDa, 60.7 
kDa, and 64.0 kDa. Protein solutions were diluted to ensure the absorbance reading 
was always between 0.l and 1. Protein concentrations were measured 3 times to ensure 
consistency and a mean value calculated. Accuracy of concentration measurements 
was checked by SDS-PAGE. 
	 M2PYK	 M1PYK	 LPYK	 RPYK	
Number of amino 
acids 
551 551 563 594 
Molecular weight 60100.21 60225.39 60685.65 63993.49 
Tetramer MW 240.4kDa 240.9kDa 242.7kDa 256.0kDa 
Theoretical pI 8.22 8.01 6.8 8.12 
Ext.	coefficient				 29910 29910 29910 35410 
Table 2. Molecular parameters of human pyruvate isoforms. 
2.2 Dynamic Light Scattering 
2.2.1 Introduction 
To study the stability of hPYKs, we used Dynamic Light Scattering (DLS) to confirm 
the protein status in solution. DLS, also known as Photon Correlation Spectroscopy 
(PCS) or Quasi-elastic light scattering (QELS), is a technique used for measuring the 
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hydrodynamic size distribution of particles, polydispersities, and aggregation effects 
in solution. A laser beam is introduced into the solution. The protein molecules 
fluctuate in solution as Brownian motion, which scatters particles. The scattering 
intensity is recorded, allowing for calculation of the molecular size using the Stokes- 
Einstein relationship. 
2.2.2 Results 
DLS assays were carried out on all hPYK isoforms after storage at -80 oC. Samples 
were thawed on ice and centrifuged at 12000 rpm at 4 oC for 15 min to remove any 
precipitates. PBS-CM was used as a blank reference, which is the same buffer used 
during the final purification step. Fifty µl of each sample (1 mg/ml) was loaded into 
the well and measured three times. 
Figure 2-5 shows the size distribution data. The “size distribution by volume” graphs 
show that single peaks from each graph present at 10 nm and the estimated protein 
molecular weights for M1PYK, M2PYK, LPYK, and RPYK are 228.0 kDa, 242.0 kDa, 
254.1 kDa, and 236.7 kDa, respectively. The molecular weights of M1PYK, M2PYK, 
RPYK and LPYK are shown Figure 2-5. Absence of multiple peaks at a higher 




Figure 2-5. Dynamic light scattering analysis of human PYK isoforms shows that all 
are stable and pure after storing at -80 ºC in PBS-CM. The molecular weights are 
estimated by the DLS software and are based on empirical mass vs. size calibration 
curve.  
2.3 Thermal shift assay 
2.3.1 Introduction 
The thermal shift assay tracks the fluorescence signal change of SYPRO Orange dye. 
The increasing temperature unfolds the protein. When the protein is unfolding in the 
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solution, the hydrophobic surface exposes and contacts with the dye, which has an 
excitation wavelength and the fluorescence signal is recorded through the whole 
process. The protein melting temperature is the temperature point when the protein 50% 
unfolds. 
The SYPRO Orange was ordered from Invitrogen (catalogue number s6650) and was 
diluted 5000x with 10 mM PBS just before use. Five µl of the diluted SYPRO Orange 
dye solution was added to 45 µl of 0.55 mg/ml protein solution or protein diluted in 
ligand solution in a 96-well PCR plate. The samples were mixed, sealed with Bio-Rad 
optical quality tape, and centrifuged to make sure the protein fully mixed with the dye. 
An i-Cycler iQ5 Real-Time PCR Detection System (Bio-Rad) recorded the 
fluorescence change from 20 to 80 oC in increments of 1 oC using an excitation 
wavelength of 485 nm and an emission wavelength of 575 nm. 
2.3.2 Results 
Figure 2-6 – Figure 2-9 demonstrate that the melting temperature for the four PYK 
isoforms are 62 oC (M1PYK), 48 oC (M2PYK), 62 oC (RPYK), and 66 oC (LPYK). 
The melting temperature for M2PYK was previously reported to be 48 ºC, which is 








   
Figure 2-6. Thermal stability of M1PYK. The left figure is the fluorescence readings. 
The right panel shows the derivative of the left –hand curve. The melting 
temperature is about 62 ºC. 
    
Figure 2-7. Thermal stability of M2PYK. The left figure is the fluorescence readings. 
The right panel shows the derivative of the left –hand curve. The melting 
temperature is about 48 ºC. 

















































































Figure 2-8. Thermal stability of RPYK. The left figure is the fluorescence reading. 
The right panel shows the derivative of the left –hand curve. The melting 
temperature is about 62 ºC. 
   
Figure 2-9. Thermal stability of LPYK. The left figure is the fluorescence reading. 
The right panel shows the derivative of the left –hand curve. The melting 
temperature is about 66 oC. LPYK melting curve shows two peaks. This might 
suggest that LPYK has two unfolding steps. 
The melting temperatures of LPYK and RPYK in the following studies in chapter 3 
changes from batch to batch by up to 3 oC. The reason of this inconstancy might be 
the protein contamination from cell culture step in each batch of protein is different. 
2.4 Analytical size exclusion chromatography 
2.4.1 Introduction 
Analytical size-exclusion chromatography performed as described by (Hugh P Morgan 
et al., 2013). hPYKs were diluted to 0.1 mg/ml and incubated overnight (18 hours) at 
room temperature before been loaded independently onto a Superdex 200 PC 3.2/30 
gel filtration column pre-equilibrated in PBS-CM at room temperature. A 25µl loop 
was used and 50 µl was injected at a rate of 0.1 ml/min. The column flow rate was 


































As shown in Figure 2-10, M1PYK, RPYK, and LPYK demonstrate single peaks, 
which are believed to be tetramers. There are two peaks in the gel filtration result of 
M2PYK. Obviously, there exists an equilibrium between the tetrameric and 
monomeric form. This results suggested that regulation of M2PYK could be due to the 
effect on the equilibrium, since tetramers are active and monomers are inactive. 
Regulation of the other isoforms might not be the same mechanism. 
 
   
Figure 2-10. Effects of low concentration (0.1 mg/ml) and long-time pre-incubation 
(18 hours) on the oligomerisation state of all four human PYKs. 
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2.5 Crystallisation trials 
2.5.1 Introduction 
Both M1PYK and M2PYK have its wild type structures (PDB: 3SRF and 4FXF) 
solved (Morgan et al., 2013a). Wild type structures of LPYK and RPYK are still not 
available. Only truncated or point mutated structures are solved (Holyoak et al., 2013, 
Valentini et al., 2002). So, we tried to crystalize wild type LPYK and RPYK, M2PYK 
with several ligands, which are tested to be natural regulators of these isoforms. 
Purified M2PYK, RPYK and LPYK samples that had been stored at -80ºC were used 
for the crystallization trials. Protein samples were thawed on ice and then mixed with 
ligand buffers to make protein incubated with 50 µM T3, 50 µM T4, 5 mM serine, 5 
mM phenylalanine, 5 mM cysteine, or 5 mM F-1,6-BP. Vapour diffusion method was 
used in the crystallization experiments. The hanging drop technique was carried in 
stable temperature room at 18 ºC. 
The drops were set up by mixing 1.5 µl of well solution with 1.5 µl of 10 mg/ml protein 
sample containing 5mM of each ligand. The well solution consisted of 6-16% PEG 
3350 or PEG 8000, 100mM sodium cacodylate (pH 6), 20 mM triethanolamine-HCl 
(TEA) buffer (pH 7.2), 50 mM MgCl2, 100mM KCl. Error! Reference source not 
found. shows the procedure for setting up the well solutions. The drops were 
equilibrated against 1ml of well solution. 
Stock solutions Final concentration of PEG 3350 or PEG 8000 (%) 6 8 10 12 14 16 
40% PEG 3350/8000 150 µl 200 µl 250 µl 300 µl 350 µl 400 µl 
1M Sodium cacodylate pH6.0 100 µl 100 µl 100 µl 100 µl 100 µl 100 µl 
1x metals buffer 100 µl 100 µl 100 µl 100 µl 100 µl 100 µl 
H2O 650 µl 600 µl 550 µl 500 µl 450 µl 400 µl 
Total volume 1 ml 1 ml 1 ml 1 ml 1 ml 1 ml 
Table 3. Procedure for preparation of well solutions used for crystallization. 1x 
metals buffer was prepared from a 10x metals buffer stock: 200mM TEA, pH 7.2, 
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500mM MgCl2, 1M KCl. All solutions were filtered using a 0.2µm syringe filter 
before use.  
2.5.2 Results 
A summary of crystals generated from conditions above are show in Figure 2-11. 
These crystals present to be pure and colourless in different shape. X-ray intensity data 
were collected at Diamond Light Source. Unfortunately, none of these crystals could 
create enough resolution diffraction intensity images to solve the structure. 
 
   
         a                                                   b                                  c 
   
         d                                               e                                    f 
   
         g                                       h                                i                            
   
         j                                          k                                     l 
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Figure 2-11. Photos of T3, T4, or amino acids co-crystallized crystals with human 
PYK isoforms: a, M2PYK with T3; b, LPYK with T3; c, RPYK with T3; d, LPYK 
with T4. Amino acids co-crystalized with human PYK isoforms: e, RPYK with 
0.01mM Cys; f, RPYK with 1mM Cys; g, RPYK with 2mM Phe; h, RPYK with 
2mM Ser; i, LPYK with 1mM Cys; j, Human PYK isoforms with natural effectors F-
1,6-BP: k, LPYK with 1mM F-1,6-BP; l, RPYK with 1mM F-1,6-BP. 
2.6 Enzymatic assays and optimization of pH 
2.6.1 Introduction 
An LDH coupled enzyme assay has been used widely in the detection of PYKs activity 
by monitoring the reaction rate (Morgan et al., 2013a, Sun et al., 2011). There are two 
assumptions made for the assay: 1) reaction 1 is zero order and irreversible. 2) reaction 
2 is first order and irreversible (McClure, 1969). A model of one auxiliary enzyme is 
used to present the model schematically Figure 2-12. 
 
Figure 2-12 Coupled enzyme assay model. Product B is removed by auxiliary 
enzyme. 
 
The mechanism of the LDH coupled assay is shown in Figure 2-13. In this assay, PYK 
catalyses the dephosphorylation reaction to generate pyruvate, which is then consumed 
and transformed to lactate by the next step. Both LDH and NADH were at saturating 
and the reaction rate of the enzymatic activity assay was measured by the monitoring 
of light at 340 nm, which is absorbed by NADH (Morgan et al., 2013a). 
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Figure 2-13. LDH-coupled enzyme reactions.  
 
To study the kinetics of PYK with/without effectors, we carried out the assay as 
follows. The PYK enzyme was sawed on ice for 10 minutes and diluted to 0.002 mg/ml 
with PBS-CM in the absence/presence of effectors. Five µl of enzyme solution was 
incubated in each well of a 96-well plate at 37 °C at pH 7.4 for 10 min. Then another 
50 µl of assay buffer (PBS-CM supplemented with 20 mM MgCl2, 200 mM KCl, 1 
mM NADH, 40 U/ml LDH) of this coupled assay was added and protein solutions of 
0.0025mg/ml PYKs were made in PBS-CM with or without addition of additives. The 
protein solutions were incubated at room temperature for 3 hours to ensure oligomeric 
equilibrium was reached.  
Meanwhile, 25ml 2x assay buffer was made (PBS-CM supplemented with 20mM 
MgCl2, 200mM KCl, 4mM ADP, 1mM NADH, and 30 U/ml LDH). Five ml of 2x 
assay buffer was removed and PEP was added to a concentration of 10 mM. Two-fold 
serial dilutions of PEP were prepared in a 96-well master block (Greiner Bio-one Cat. 
No. 780270) using 2x assay buffer to yield PEP concentrations ranging from 78 µM 
to 10 mM (final assay concentrations 39 µM to 5 mM). A multi-channel pipette was 
used to transfer 50 µl of each PEP dilution to a column of a 96-well plate (Greiner Bio- 
one Cat. No. 655101). 
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The reaction (Figure 2.2) was initiated by adding 50 µl of protein solution to the PEP 
solutions in the 96-well plate using a multi-channel pipette. Final concentrations of 
reagents were as follows: 0.00125 mg/ml MPYK, 10 mM MgCl2, 100 mM KCl, 2 mM 
ADP, 15 U/ml LDH, 0.5 mM NADH, and PEP concentrations ranging from 39 µM to 
5 mM. Plates were agitated for 10 seconds before measuring the decrease in 
absorbance at 340 nm for 5 min using a plate reader (SpectraMax M5 multimode plate 
reader, Molecular Devices). Initial reaction rates were obtained using SoftMax Pro 
software. Substrate-velocity graphs were plotted using Kaleidograph (Synergy 
Software). 
2.6.2 Results 
In this assay, M1PYK, M2PYK, LPYK and RPYK were diluted to 0.001 mg/ml from 
23 mg/ml, 19 mg/ml, 16 mg/ml and 8.1 mg/ml, respectively. (a) Km for M1PYK is 
stable from pH 7.5 to 6.0. The Vmax of M1PYK is about 40% higher at pH 6.5-7.0 than 
at pH 6.0 and pH 7.5. In (b) (c) (d), Km (PEP) for M2PYK RPYK and LPYK decrease 
from 3.7, 2.5, and 1.5 mM to 0.17, 0.16 and 0.15 mM, respectively. We conclude that: 
1) Optimised pH for M1PYK, M2PYK, LPYK, and RPYK is between 6.5-7.0. 2) 
Substrate binding of M2PYK, LPYK, and RPYK is tighter in lower pH buffer. 




                             a                                                                b 
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                              c                                                               d 
Figure 2-14. The effect of pH on human pyruvate kinases enzyme activity. The unit 
of Vmax is unit/mg/ml. One enzyme activity unit will convert 1.0 µmole of PEP to 
pyruvate per minute at RT at its specific pH. Unit of Km is mM. 
 
(a) The effect of pH changing influenced the Vmax of M1PYK. The maximum Vmax 
was 105.1 and 99.98 when pH was 7.0 and 6.5, respectively. When pH was 7.5 or 6.0, 
Vmax decreased to 64.72 and 72.65. 
(b) The effect of pH changing influenced the Vmax of M2PYK. The maximum Vmax 
was 122.9 when pH was 7.0. When pH was 6.0, Vmax decreased to 75.91. 
(c) The effect of pH changing influenced the Vmax of LPYK. The maximum Vmax was 
104.8 when pH was 7.0. When pH was lower or higher, Vmax decreased to 64.04, 52.33 
and 39.65. The Km of PEP decreased from 1.5 to 0.15 from pH 7.5 to pH 6.0. 
(d) The effect of pH changing influenced the Vmax of RPYK. The maximum Vmax was 
114.5 and 95.39 when pH was 7.0 and 6.5, respectively. When the pH was 7.5 or 6.0, 
Vmax decreased to 64.72 and 72.65. The Km of PEP decreased from 3.7 to 0.17 from 
pH 7.5 to pH 6.0. 
2.7 Conclusion 
All four His6-tagged human pyruvate isoforms were successfully expressed and 
purified. The yield is around 12 mg/L and purity is > 95%. The proteins are stable in 
the storage condition (-80 °C). The protein was used to carry out crystallization trials 
and a group of crystals were produced, but unfortunately none of them diffract to 









CHAPTER 3. Redox and time dependant regulation on 
PYK isoforms 
3.1 Introduction 
Redox status plays an important role in regulation of cell survival. Moderate levels of 
reducing and oxidative molecules ensure redox homeostasis, which differs 
significantly between various tissues (Trachootham, Lu, Ogasawara, Nilsa, & Huang, 
2008). Redox status affects both signalling protein functions and enzyme activity. 
More recent works show that redox status regulates enzyme activity significantly. For 
example, LMW-PTP (low molecule weight protein tyrosine phosphatase) could be 
oxidized by H2O2 (hydrogen peroxide) or nitric oxide which leads to irreversible 
enzyme activity loss (Chiarugi et al., 2001).  
3.1.1 Redox status of cell microenvironment has a profound effect on 
tumorigenesis 
Redox status, the balance between reduced state and oxidized state in the cell 
microenvironment, is one of the three basic states that need to be altered in fast 
dividing normal cells and tumour cells (Cairns, Harris, & Mak, 2011). The other two 
are ATP generation and macromolecule synthesis. Because redox status is important 
in cancer cell survival (Anastasiou et al., 2011) and is different with normal cells, it is 
reasonable to suggest that activity of enzymes in the glycolytic pathway might be 
regulated by redox environment.  
3.1.2 Redox influences on cancer cells 
In human lung cancer cells, the intracellular concentration of ROS (reactive oxygen 
species) inhibits M2PYK activity and then promotes metabolic flux to meet the 
requirement of cell proliferation (Anastasiou et al., 2011). It was also reported that 
redox state regulates the enzymatic activity and oligomerisation state of M2PYK 
(Brimacombe et al., 2010).  
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3.1.3 Redox influences red blood cells 
In red blood cells (RBCs), the glycolytic pathway is the only ATP generating path as 
RBCs do not contain mitochondria. In red blood cells, RPYK catalyses PEP to 
pyruvate reaction, which generates one molecule of ATP as cofactor and one molecule 
of pyruvate. Then, the conversion of pyruvate to lactate is catalysed by lactate 
dehydrogenase. Lactate is secreted as the final product of erythrocyte glycolysis. We 
know that ATP is a vasodilatory signalling molecule and in response to the increased 
shear stress will help arteries and capillaries to expand in order to speed up circulation 
and further regulate human body blood pressure (Wan, Ristenpart, & Stone, 2008). 
The canonical role of red blood cells is oxygen and carbon dioxide transportation. They 
are also equipped with a redox buffer systems (Kuhn et al., 2017). The system contains 
antioxidant molecules and redox couples, including reduced and oxidized glutathione 
(GSH/GSSG), ascorbate/dehydroascorbate (vitamin C), and α-tocopherol (vitamin E); 
and reducing equivalents including NADH and NADPH; and many antioxidant 
enzymes. This system is very important to maintain haemoglobin in a reduced form 
and keep alive. It is reported that redox dysfunction is related to anaemia. During the 
anaemia, the ATP production from glycolysis pathway might change in red blood cells 
if the redox environment change.  
 
Figure 3-1. Redox regulation in red blood cell from Kuhn’s article (Kuhn et al., 
2017). Superoxide dismutase (SOD), catalase (Cat), glutathione peroxidase (GPx), 
and peroxiredoxin 2 (Prx2). oxidized glutathione (GSH/GSSG). 
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3.1.4 Redox influences liver cells 
The redox status of the liver is strictly controlled in hepatocytes by the balance of 
oxidant and antioxidant molecules. During pathogenic events caused by metabolic and 
proliferative disorders, oxidative stress is the major cause of liver damage (Cesaratto, 
Vascotto, Calligaris, & Tell, 2004). Several enzymatic markers and non-enzyme 
markers related to redox status are used to detect and monitor the level of liver damage. 
It has also been shown that the rate of ATP generation is related to hypoxia (Z. F. Jiang, 
Wang, Xu, & Ning, 2017).  This suggests that ATP generation is relevant to the redox 
environment.  
To investigate the role of oxidation on PYK and its possible effect on liver damage, 
we investigated RPYK activity changes under various redox states by adding different 
amounts of the reductant DTT and the oxidant H2O2 to the enzyme assay. The 
allosteric activator F-1,6-BP was used as a positive control. 
3.1.5 Pre-incubation time control is important in enzymatic assays 
To explain the strictly controlled pre-incubation time, a diagrammatic drawing of the 
relationship between pre-incubation time and enzyme activity is shown in Figure 3-2. 
The enzymatic activity drops gradually during our experiment especially in the 
enzymatic assay of M2PYK. At different periods of pre-incubation, the difference 
between the activated, control and inhibited specific enzymatic activity also enlarges 
by time. It was very important to keep the same pre-incubation time in all experiments 
performed in the following study. We chose 10 min pre-incubation time to give enough 
time for protein in solution to reach equilibrium (from the initial oligomeric state to 
regulated state) and to avoid the inaccuracy by fast pipetting especially when we screen 
a long list of compounds and at the same time to maintain most enzymatic activity. 
The pre-incubation time is different from the assay time (usually lasting 200-300 s), in 
which the 340-nm absorbance was recorded. The assay time always starts when the 
protein solution (enzyme or enzyme with ligand) was added into the PEP solution (PEP, 
ADP, MgCl2, KCl, LDH, NADH).  
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The only exception about pre-incubation time in this study is the time-dependant assay. 
For example, in Chapter 3.4.2 the pre-incubation time is from 0 min to 150 min, and 
in Chapter 3.5 the pre-incubation time is from 0 min to 20 min. 
 
Figure 3-2. Diagrammatic drawing of the relationship between pre-incubation time 
and enzyme activity. Orange dots represent enzymatic activity of M2PYK with 
activator; blue dots are M2PYK alone; red dots are M2PYK with inhibitor. 
3.2 Regulation of four human isoforms of PYK by reducing reagent 
Four human PYKs work in various reducing environments and with natural regulators. 
To compare the effects of reducing reagent on these isoforms, we tested all four 
isoforms of hPYK via a series of enzymatic assays by adding 1 mM DTT and 1 mM 
F-1,6-BP. DTT (dithiothreitol) is a common reducing reagent used in protein assays to 
prevent oxidation and disulphide bond formation between cysteine groups in proteins. 
All experiments were carried out under sub-saturating substrate concentrations with 
an incubation time of 10 min. 
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Figure 3-3. Four isoforms of human PYK enzyme activity data in addition of 1mM 
DTT, 1mM and control (protein alone). Assay condition is that 2mM ADP, 100mM 
KCl, 10mM MgCl2, in PBS-CM, pH 7.4, at room temperature. The pre-incubation 
time with ligands after dilution was 10 minutes. One enzyme activity unit will 







		 		 M1PYK	 M2PYK	 LPYK	 RPYK	
control	
Vmax	
(unit/mg)	 144.3 39.67 68.9 48.88 
		 Km	(mM)	 0.74 0.51 0.28 2.8 
DTT	
Vmax	
(unit/mg)	 168.1 81.75 92.16 72.56 
		 Km	(mM)	 0.82 2.66 0.43 0.93 
F-1,6-BP	
Vmax	
(unit/mg)	 148 72.7 69.45 57.02 
		 Km	(mM)	 0.61 0.38 0.18 0.27 
Table 4. A table of four isoforms Km and Vmax values. 
 
From the above assay, we could conclude that DTT seems to up regulate all PYKs 
even Vmax for M1PYK is increased by 10% even though it is the most stable isoform 
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and is constitutively active. To exclude the effect of DTT on LDH, we tested 2mM 
DTT with LDH and found out that DTT did not change the activity of LDH.  Another 
observation is that the effector molecule F-1,6-BP activates M2PYK, RPYK and 
LPYK but not M1PYK, confirming earlier reports (Carminatti, Jiménez de Asúa, 
Leiderman, & Rozengurt, 1971; Jurica et al., 1998; Giovanna Valentini et al., 2002).  
3.3 The effect of redox on activity of RPYK 
Redox regulation may play a particularly important role in blood given the high 
oxygen concentrations. Glycolysis may also play a different role in red blood cells as 
they share the same characteristic as blood-stream form trypanosomes in that they do 
not have a functioning mitochondrion and they rely on glycolysis to produce ATP 
rather than oxidative phosphorylation (Bakker, Michels, Opperdoes, & Westerhoff, 
1997; Tilton, Seaman, Carriero, & Piomelli, 1991). To investigate the potentially 
unique regulation of RPYK, we studied enzyme activities in a range of reducing and 
oxidized conditions, and compared them with the effect of the allosteric activator F-
1,6-BP.  
The first experiment was to measure the effect of reducing agent dithiothreitol (DTT) 
on the activity of RPYK. DTT (HSCH2CH(OH)CH(OH)CH2SH) is a common 
reducing reagent used in protein assays to prevent oxidation and disulphide bond 
formation between cysteine groups in proteins.   
As described in chapter 2, the enzyme activity assay was set up at room temperature 




		 RPYK	 RPYK+FBP	 RPYK+DTT	 RPYK+DTT+FBP	
	
Vmax	(unit/mg)	 84.6 102.5 110.5 98.4 
		
Km	(mM)	 6.3 0.39 1.6 0.33 
 
Figure 3-4. Enzyme activity assay with PEP titration shows that both F-1,6-BP and 
DTT could activate RPYK. Assay conditions are pH 8.0, 25 ºC, 2mM ADP 
(saturating). Unit definition is that one unit will convert 1 µmol of PEP to pyruvate 
per min at pH 8.0 at 25 ºC. The pre-incubation time with ligands after dilution was 
10 minutes. 
 
DTT (2mM) on its own can also activate RPYK, activity at 1.25 mM PEP (sub-
saturating) from about 20 unit/mg to 50 unit/mg and at the same time, Km of RPYK 
reduced from 6.338 mM to 1.62 mM. Compared with natural activator F-1,6-BP, DTT 
seems to be a weaker activator. F-1,6-BP activates RPYK from 20 unit/mg to around 
80 mg/ml as shown in Figure 3-4. When DTT and F-1,6-BP are added together, there 
is no additional effect over that of F-1,6-BP alone. 
Can oxidation affect RPYK activity? 
Firstly, we tested whether dissolved oxygen in buffer might provide an oxidizing 
environment. RPYK protein in degassed buffer shows marginal activation compared 
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with non-degassed buffer as the Km (PEP) increased from 3 mM to 14.71 mM in the 
more oxidising environment. The Vmax of the non-degassed buffer could not be 
accurately determined because of poor curve fitting. 
Secondly, we test the effect of reducing agent on RPYK activity. Changing DTT 
concentration from 2mM to 1mM results in a drop of Vmax from 92.06 unit/mg to 62.96 












(unit/mg)	 Fitting failure 67.1 63.0 92.1 
		 Km	(mM)	 14.7 3.1 1.4 0.36 
 
Figure 3-5. Enzymatic assay of RPYK with reducing reagent DTT. Assay condition 
are pH 8.0, 25 ºC, 2mM ADP (saturating). Unit definition is that one unit will 
convert one µmol of PEP to pyruvate per min at pH 8.0 at 25 ºC. The pre-incubation 
time with ligands after dilution was 10 minutes. 
These results show that the enzymatic activity of RPYK is much higher in the reduced 
state (Km (non-degassed)>Km (degassed) >Km (1mM DTT) >Km (2mM)). A likely 
explanation for these observations might be that cysteine oxidation in RPYK results in 
low enzymatic activity. 
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3.3.1 How do Redox reagents affect thermal stability of RPYK and LPYK? 
Thermal denaturation assay results show that DTT increases melting temperatures of 
RPYK and LPYK. In the presence of 1mM DTT the melting temperatures of RPYK 
and LPYK are increased by 1.5ºC and 3ºC respectively indicating that DTT has a 
stabilising effect on the structure of the enzyme as demonstrated in Figure 3-5 b. On 
the other hand, the melting temperatures of protein with 1 mM H2O2 for both RPYK 
and LPYK showed almost the same melting temperature compared with the control in 
Figure 3-4 and Figure 3-5. In addition, as a positive control experiment, enzyme with 







Figure 3-6. Thermal denaturation data for RPYK and in the presence of 1mM DTT, 
1mM H2O2, 1mM F-1,6-BP or with no additives. The upper figure shows the change 
in fluorescence on increasing temperature. The bottom panel is the rate of change of 
fluorescence with respect to temperature.  The melting temperature is   64 ºC (R 









































Figure 3-7. Thermal denaturation data for RPYK and in the presence of 1mM DTT, 
1mM H2O2, 1mM F-1,6-BP or with no additives. The upper figure shows the change 
in fluorescence on increasing temperature. The bottom panel is the rate of change of 
fluorescence with respect to temperature.  The melting temperature is at about 66 ºC 
(L control), 66 ºC (L+DTT), 66 ºC (L+H2O2), and 64.5 ºC (L+F-1,6-BP). 
 
Melting temperature of both LPYK and RPYK were not influenced much by H2O2 but 
both DTT and F-1,6-BP show measurable effects with increased stability correlating 
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PYKs, we studied three concentrations (0.1mM, 1mM, 10mM) to find out whether the 





Figure 3-8. Thermal denaturation data for RPYK and in the presence of 0.1mM DTT, 
1mM DTT, 10mM DTT or with no additives. The upper figure shows the change in 
fluorescence on increasing temperature. The bottom panel is the rate of change of 
fluorescence with respect to temperature.  The melting temperature is at about 62 ºC 
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Figure 3-8 shows clearly that increasing reducing reagent concentration increases 
RPYK stability. By adding 0.1mM DTT, 1mM DTT and 10mM, melting temperature 
was increased by 0.5 ºC, 2.5 ºC and 2 ºC. We could also conclude that around 1mM is 
the concentration that gives maximum effect on melting temperature. It is not clear 
why higher concentrations (10mM) of DTT should have a lesser effect. The reason 
might be the saturation of DTT is just 1 mM but to confirm this phenomenon we need 


















Figure 3-9. Thermal denaturation data for LPYK and in the presence of 0.1mM DTT, 
1mM DTT, 10mM DTT or with no additives. The upper figure shows the change in 
fluorescence on increasing temperature. The bottom panel is the rate of change of 
fluorescence with respect to temperature.  The melting temperature is at about 66ºC 
(L control), 66 ºC (L+0.1mM DTT), 65.5 ºC (L+1mM DTT), and 65.5 ºC (L+10mM 
DTT). 
 
Figure 3-9 shows that the melting temperature of LPYK seems to be stable and not 
affected by DTT much (control 66 ºC, + 0.1 mM DTT 66 ºC, + 1 mM DTT 65.5 ºC, + 
10 mM DTT 65.5 ºC). In addition, the melting temperature of protein alone is about 
66 ºC, which is much higher than 63 ºC in the Figure 4-4. This might cause by different 
batch protein contains different protein contaminations, which might affect melting 
temperature. However, we still could see the trend that the curve goes deep as the DTT 
concentration increased from 0mM to 1mM. 1mM and 10mM DTT shows almost the 
same effect on LPYK. 
3.4 Time dependant regulation 
An important observation made over the course of running these various enzyme 
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incubation time after diluting the protein and longer pre-incubation times could 
significantly reduce enzyme activity. To explore this phenomenon, we carried out a 
series of time dependant enzyme assays to test how pre-incubation time regulates the 
enzyme activities of human pyruvate kinase. In particular, it is important to understand 
the mechanism of this time-dependent change which could be the result of a slow 
dissociation (or conformational change) of the active tetrameric form in a more dilute 
environment. Alternatively, it may be an oxidation effect or perhaps gradual 
denaturation of the protein. To explore these possibilities, we set out to answer the 
following questions.  
• Do all human PYK isoforms activity change over time? 
• Do reducing reagent and natural activator affect the time-dependant activity 
change? 
• Is the time-dependant activity changing reversible?  
3.4.1  Single point assay shows that PYKs loose enzyme activity after 
dilution 
To examine this phenomenon more carefully, we have studied enzymatic activity at a 
series of pre-incubation times. All four isoforms were studied using the coupled 
enzyme assay described in chapter 2. After dilution from high storage concentration 
(23mg/ml to 0.001mg/ml), M1PYK activity maintained at about 160 unit/mg. 
However, the other three isoforms, M2PYK, LPYK and RPYK, which were stored at 
13.0mg/ml, 16mg/ml and 8.1mg/ml, respectively, lost most of their activity after 
dilution. Decreasing protein activity is much higher in the first 50 minutes during 
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which time half of the activity is lost; another 300 minutes is required to decrease 
activity to near zero. 
 
Figure 3-10. The horizontal axial represents pre-incubation time from 0 min to 420 
min. M1PYK (blue) shows steady activity; all other three isoforms activity decreases 
after dilution immediately. Assay condition are pH 8.0, 25 ºC, 1mM ADP (sub 
saturating). Unit definition is that one unit will convert one µmol of PEP to pyruvate 
per min at pH 8.0 at 25 ºC.  
 
We can see from Figure 3-8 that the only isoform that maintains enzyme activity is 
M1PYK. Even after 150 minutes, M1PYK was still fully active. The other 3 isoforms 
lost their activity rapidly; the half-lives of M2PYK, RPYK and LPYK activities are 30 
minutes, 200 minutes and 150 minutes, respectively. 
The most likely reasons for the differences in behaviour of the four human isoforms 
are:  
• Constitutively active M1PYK is most stable and least prone to dissociation on 
dilution  































To investigate these possibilities, a series of further experiments were carried out. 
 
 
3.4.2 Reducing reagent and/or activator slows down loss of activity 
In the previous Chapter 3.3.1, we showed the effect of reducing reagent DTT and F-
1,6-BP on activities of all four human PYK isoforms. To further study the time-
dependent activity loss of RPYK, a matrix of conditions was designed to study the 
effect of DTT and F-1,6-BP over time (outlined in Table 5). A key parameter in the 
activity assay is the time taken from diluting the protein from its stock concentration 
(> 10 mg/ml) to the concentration used to measure rate of reaction (< 0.01 mg/ml). 




Table 5. All four isoforms of human PYKs were tested at 0.001mg/ml with  varying 
pre-incubation times (from 0 min to 150 mins) in four sets of PBS buffer (+F-1,6-
BP/+DTT, -F-1,6-BP/+DTT, +F-1,6-BP/-DTT, -F-1,6-BP/-DTT). LPYK, RPYK, 
M1PYK and M2PYK protein were diluted to 0.001mg/ml from 16mg/ml, 8.1mg/ml, 
23mg/ml and 13mg/ml, respectively. Assay condition are pH 8.0, 25 ºC, 2mM ADP 
(saturating). Unit definition is that one unit will convert one µmol of PEP to pyruvate 
per min at pH 8.0 at 25 ºC.  
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For each enzyme, four complete sets of enzymatic curves were measured. The effector 
F-1,6-BP has been found to stabilise the tetramer form of M2PYK (Morgan et al., 
2013a). We hypothesised that one reason of loss activity over time especially at dilute 
concentrations would be the dissociation of active tetramers into inactive monomers. 
Therefore, the enzyme activity was measured with and without F-1,6-BP with pre-
incubation time from 0 to 150 minutes. Similarly, the effect of reducing agent 
incubated over the same period was tested at the same time. 
In the following sets of experiments, each condition for each isoform was carried out 
in triplicate in two completely independent studies. For all experiments, the results 
were highly consistent between two independent runs. Graphs for only one of the sets 
of experiments are shown below.  




                             (a)                                                                      (b) 
 
(c)                                                                          (d) 
Figure 3-11. The effect of pre-incubation time, DTT and F-1,6-BP on M1PYK 
enzymatic activity. The first line of the boxes gives the Vmax, the second line Km 
values. (a)The effect of dilution reduced Vmax from 129.5 to 103.8 in 150 minutes 
with 1mM DTT and 1mM F-1,6-BP in solution, (b) reduced Vmax from 162.0 to 
123.8 in 150 minutes with 1mM DTT in solution. Km of PEP was stable, (c) reduced 
Vmax from 162.1 to 118.8 in 150 minutes with 1mM F-1,6-BP in solution, and (d) 
reduced Vmax from 151.6 to 121.4 in 150 minutes in PBS solution. 
 
Figure 3-11 shows that at time zero point, Vmax for M1PYK is 150 unit/mg compares 
to Vmax (160 unit/mg) of M1PYK when F-1,6-BP was added. This 10% difference in 
activity is not significant and fits with the published literature which shows no 
significant increase in activity of M1PYK on addition of F-1,6-BP (Iovine et al.).  
Similarly, addition of 1 mM DTT does not significantly affect Vmax (160 unit/mg) of 
M1PYK. However, when DTT and F-1,6-BP are added together, Vmax decreases by 
20% compared with the other three conditions. Therefore, the question is whether there 
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is a genuine inactivating effect on adding both DTT and F-1,6-BP together. However, 
this is difficult to reconcile with the observation that individually DTT and F-1,6-BP 
slightly activate the enzyme. 
 
Figure 3-12. Vmax of M1PYK in 150 minutes pre-incubation in four conditions. 
 
Figure above shows that Vmax is not strong affected by addition of F-1,6-BP and DTT. 
The time dependant enzyme activity loss was not obvious for M1PYK. Half-life of 
protein activity was longer than 150 minutes in all four conditions as after 150 minutes’ 
pre-incubation protein activities are above 100 unit/mg. According to stable Km data 
(range from 0.5 mM to 0.7 mM), substrate binding was not affect by pre-incubation, 
F-1,6-BP or reducing agent. 


























                             (a)                                                                      (b) 
 
                              (c)                                                                      (d) 
Figure 3-13. The effect of  pre-incubation time, DTT and F-1,6-BP on M2PYK 
enzymatic activity (a) The effect of dilution reduced Vmax from 82.5 to 38.4 in 150 
minutes with 1mM DTT and 1mM F-1,6-BP in solution, (b) reduced Vmax from 89.4 
to 23.17 in 150 minutes with 1mM F-1,6-BP in solution, (c) reduced Vmax from 89.9 
to 27.13 in 150 minutes with 1mM F-1,6-BP in solution, and (d) reduced Vmax from 
103.0 to 11.62 in 150 minutes with 1mM F-1,6-BP in solution. Vmax of all M2PYK 




Figure 3-14. Variation of Vmax of M2PYK over 150 minutes pre-incubation time in 






























Figure 3-11 shows calculated Vmax values suggesting that the addition of the activators 
(DTT or F-1,6-BP) individually or in combination result in a slightly lower M2PYK 
enzymatic activity of 80 unit/mg compared with the M2PYK on its own which has an 
activity of over 100 unit/mg. However, the curves in Figure 1-11 clearly show that 
both DTT and F-1,6-BP activate the enzyme at lower more physiologically relevant 
concentrations of PEP substrate. In keeping with that, M2PYK alone shows the most 
sigmoidal shaped activity curves at 0 minute as shown in Figure 3-13 while addition 
of F-1,6-BP results in more hyperbolic shaped curves. We could conclude that F-1,6-
BP helps M2PYK to reach higher activity at low PEP concentration as Km (-DTT/-F-
1,6-BP) > Km (+DTT/-F-1,6-BP) > Km (+DTT/+F-1,6-BP) > Km (-DTT/+F-1,6-BP). 
DTT is however a much weaker activator at low PEP concentrations suggesting that 
F-1,6-BP increases the protein-substrate binding but this effect is reduced in the 
presence of DTT.   
In Figure 3-12, DTT (Canault et al.) or F-1,6-BP (Cheng et al.) or DTT & F-1,6-BP 
(blue) in PBS solution all slow down the time dependant enzymatic activity loss 
compared to protein alone (yellow). Half-life increased from 10 minutes to 15 min 
(DTT), 60 min (F-1,6-BP) and 150 min (DTT & F-1,6-BP), respectively. 
The phenomenon of the biphasic loss of activity is interesting compared with the 
relative results in this Chapter of other isoforms. There are two possible explanations: 
The oxidation of the cysteine residues on the surface of the protein leads to activity 
loss and then the dissociation from tetramer to monomer leads to more activity loss; 
or the dissociation itself occurs in two steps: tetramer-dimers, dimers-monomers with 
dimers still having some activity. 
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The effect of DTT, F-1,6-BP, and pre-incubation time on the Vmax of LPYK 
  
                             (a)                                                                      (b) 
 
  
                             (c)                                                                      (d) 
Figure 3-15. The effect of pre-incubation time, DTT and F-1,6-BP on LPYK 
enzymatic activity (a) The effect of dilution reduced Vmax from 83.9 to 43.13 in 150 
minutes with 1mM DTT and 1mM F-1,6-BP in solution. But the binding of 
substrates increased. Km of PEP decreased from 0.69mM to 0.014mM in 150 
minutes. (b) The effect of dilution reduced Vmax from 90.43 to 51.41 in 150 minutes 
with 1mM DTT in solution. But the binding of substrates increased. Km of PEP 
decreased from 0.73mM to 0.26mM in 150 minutes. (c) The effect of dilution 
reduced Vmax from 83.3 to 47.8 in 150 minutes without DTT but with 1mM F-1,6-BP 
in solution. However, the binding of substrates increased in 15 minutes but decreased 
after longer pre-incubation. (d) The effect of dilution reduced Vmax of LPYK from 
91.0 to 28.6 in 150 minutes in PBS only. 
 
Strangely, the affinity decreased and Vmax increased when DTT or/and F-1,6-BP were 
added. This is similar to the RPYK results in the following assays. The reason might 
be the misuse of software (Prism Version 7.0b) in the data analysis. To further 
investigate this phenomenon, more repeats need to be performed. If it is reproducable, 
structure information of M2PYK co-crystallised with F-1,6-BP will be required. 
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Figure 3-16. Vmax of LPYK over 150 minutes pre-incubation time in the presence or 
absence of DTT and F-1,6-BP. 
 
At start point (0 minute), enzymatic activities of LPYK in four conditions are around 
85 unit/mg at a PEP concentration was of 8mM. It seems therefore that adding DTT, 
F-1,6-BP or DTT & F-1,6-BP gives no immediate activation effect.  However, DTT, 
F-1,6-BP or DTT & F-1,6-BP do significantly slow down the time dependant 
enzymatic activity loss, suggesting that after a pre-incubation period, the protein in 
PBS solution with DTT or F-1,6-BP or DTT & F-1,6-BP maintained higher enzyme 
activities than protein alone. 
Interestingly, protein with DTT or DTT & F-1,6-BP shows a higher Km, which means 
DTT might weaken the substrate binding at low PEP concentrations and this is 
consistent with the results found for M2PYK in the previous section though for LPYK 
F-1,6-BP does not appear to increase the protein substrate binding. 



























   
                             (a)                                                                      (b) 
 
                             (c)                                                                      (d) 
Figure 3-17. The effect of pre-incubation time, DTT and F-1,6-BP on RPYK 
enzymatic activity (a) The effect of dilution reduced Vmax from 70.3 to 43.13 in 150 
minutes with 1mM DTT and 1mM F-1,6-BP in solution. But the binding of 
substrates increased. Km of PEP decreased from 1.32mM to 0.29mM in 150 minutes. 
(b) The effect of dilution reduced Vmax from 75.14 to 32.46 in 150 minutes with 
1mM DTT and 1mM F-1,6-BP in solution. But the binding of substrates increased. 
Km of PEP decreased from 1.85mM to 0.99mM in 150 minutes. (c) Effect of dilution 
reduced Vmax from 72.74 to 43.62 in 150 minutes with 1mM F-1,6-BP in solution. 
But the binding of substrates was tightest at 30 minutes. (d) The effect of dilution 
reduced Vmax from 56.6 to 15.14 in 150 minutes in PBS solution. 
 
 
Figure 3-18. Vmax of RPYK over 150 minutes pre-incubation time in the presence or 


























Figure 3-18 shows that with very short pre-incubation times (immediately after the 
enzyme is diluted from the higher concentration stock solutions) RPYK activity was 
increased from 55 unit/mg to about 75 unit/mg by DTT, F-1,6-BP or DTT & F-1,6-
BP. Surprisingly, RPYK with DTT or DTT & F-1,6-BP shows lower activity at low 
PEP concentrations, which means DTT might reduce the PEP-protein binding at low 
substrate concentrations. We can see from Figure 3-18 that Km (F-1,6-BP) and Km 
(protein alone) are about 0.5 mM but Km (F-1,6-BP) and Km (DTT & F-1,6-BP) are 
1.3 mM and 1.8 mM, respectively. This is similar to the effect of DTT on LPYK. F-
1,6-BP also cannot increase the protein-substrate binding, which is also similar to 
LPYK. 
Conclusion and discussion 
M1PYK activity is retained in all conditions as both Vmax and Km were not significantly 
affected by reducing agent or activator. This is in contrast with the enzymatic activities 
of RPYK, LPYK, and M2PYK for which the activity decreases quickly after dilution 
in PBS solution. This loss of activity is however considerably slowed by the addition 
of DTT or F-1,6-BP or a combination of DTT + F-1,6-BP. 
The Km value of four isoforms incubated with/without DTT or F-1,6-BP are 
summarized in Table 6. For M2PYK addition of F-1,6-BP decreases the Km of the 
substrate PEP at low PEP concentrations. The change of Km for PEP binding by 1,6-
BP was not however significant for (PEP) RPYK (from 0.291 mM to 0.287) and LPYK 
(from 0.442 mM to 0.0.479 mM). DTT decreases the Km of PEP by decreasing protein 
substrate binding of RPYK and LPYK. But DTT does not appear to decrease substrate 





Km	(PEP)	mM	 M1PYK	 M2PYK	 RPYK	 LPYK	
control	 0.57	 1.77	 0.29	 0.44	
add	1mM	DTT	 0.72	 1.23	 0.73	 1.84	
add	1mM	FBP	 0.55	 0.38	 0.29	 0.48	
Table 6. Km values (expressed in mM) of four isoforms incubated with/without DTT 
or F-1,6-BP. 
3.4.3 Reducing reagents help RPYK to maintain activity or recover activity 
To find out whether the activity loss is reversible, we tested different time points to 
add reducing agent through a set of time dependant enzymatic activity assays. Three 
time points (0 minute, 10 minutes and 180 minutes) after dilution were chosen and     











Figure 3-19. The effect of DTT on recovering the activity of RPYK. RPYK was 
diluted from 8.1mg/ml to 0.001mg/ml. (a) The protein was diluted in to PBS with 
2mM DTT. After dilution, the effect of protein activity decreases slowly from 140 
unit/mg to 100 unit/mg in 220 minutes. (b) After 3 hours, 2 mM DTT was added into 
the protein solution, the enzyme activity could not be recovered. (c) After 7 minutes, 
2 mM DTT was added into the protein solution, the enzyme activity was recovered 
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gradually and maintain a higher activity. (d) Three charts are put together to compare 
the absolute enzymatic activity values. 
 
The results presented in Figure 3-19.  show that the presence of DTT helps to maintain 
a significant amount of enzyme activity compared with the rapid loss of activity 
observed for RPYK alone. Importantly, addition of DTT can partially recover enzyme 
activity suggesting that the mechanism of activity loss is reversible ( i.e. activity loss 
is not caused by protein denaturation or aggregation), but more probably related to 
oxidation of cysteines and their role in stabilising the active tetrameric form of RPYK. 
3.4.1 Both DTT and TCEP maintain RPYK activity over time. 
DTT is not a stable reducing agent in aqueous solution and is easily oxidized over time. 
Another reducing agent TCEP that is more stable was tested with RPYK to rule out 
the possibility that the decrease of enzyme activity over time was affected by 
spontaneous oxidation of DTT.  
 
Figure 3-20. Enzyme activity of RPYK alone, with 2 mM DTT or with 2mM TCEP. 
Both 2 mM DTT and 2 mM TCEP activated RPYK activity. The activity of the protein 
with both DTT and TCEP decreases gradually over time. In 420 minutes, the protein 
still has activity: about 40 unit/mg compared with a control of almost 0 activity. 
3.4.2 The effect of DTT and GSH on M2PYK 
In 2011, it was shown that the oligomerisation state of M2PYK and its enzymatic 
activity relies on redox state (Anastasiou et al., 2012). The cysteine-containing 
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tripeptide glutathione (GSH) is one of the major biological redox regulators. Here we 
compared the effects of the artificial reducing reagent DTT and GSH on enzyme 
activity of M2PYK. 
In this assay, M2PYK was diluted to 0.002 mg/ml and incubated with GSH for 10 min. 
Then, assays were performed in 100 mM KCl, 10 mM MgCl2, pH 7.4, in PBS-CM, at 
room temperature (25 oC), pre-incubation time 10 min and final protein concentration 
0.001 mg/ml. 
  
















































Figure 3-21. Effects of DTT and GSH on enzyme activity of M2PYK. Error bars are 
derived from three independent repeat experiments. 
 
As shown in Figure 3-21. , M2PYK is upregulated by both reducing reagents from 10 
unit/mg to above 30 unit/mg. These effects suggest that M2PYK is sensitive to redox 
environment. They further suggest that it is a biophysical effect of the reduction 
potential of GSH and DTT rather than a possible specific binding effect of either of 
the additive molecules. 
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3.4.3 Pre-incubation time affects melting temperatures of LPYK and RPYK 
As long time pre-incubation affects protein activity, it is important to test what role 
protein stability plays. We studied the protein stability of RPYK and LPYK after pre-
incubation (20 hours) with and without DTT through thermal denaturation assays. 
Dilution and pre-incubation not only regulated enzyme activity but also affect the 
melting temperatures of both RPYK and LPYK. 
 
Figure 3-22. RPYK was incubated at room temperature for 20 hours at 0.1mg/ml 
with or without 1mM DTT. The figure shows derivative calculations of the 
fluorescence readings. The melting temperature is at about 62 ºC (R control), 64.5 ºC 
(R + 1mM DTT), 63.5 ºC (R 20 hours of pre-incubation), and 64.5 ºC (R + 1mM 


















R R+1mM	Dtt R	20hours	incubation R+1mM	Dtt	20hours	incubation
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As shown above, after 20 hours of pre-incubation, the melting temperature of RPYK 
alone increased form 62 ºC to 63.5 ºC. However, RPYK with 1mM DTT show stable 
protein even after 20 hours of pre-incubation. This result is in line with the time 
dependant enzyme activity assay and suggests a correlation between enzyme stability 
and enzyme activity. 
 
 
Figure 3-23. LPYK was incubated at room temperature for 20 hours at 0.1mg/ml. 
The figure shows derivative calculations of the fluorescence readings. The melting 
temperature is at about 61.5 ºC (L control), 66ºC (L + 1mM DTT), 66 ºC (L 20 hours 
of pre-incubation), and 66 ºC (L + 1mM DTT + 20 hours of pre-incubation). 
 
3.4.4 Analytical gel filtration shows M2PYK dissociates into monomers 
Previous research showed that M2PYK dissociates slowly after dilution from high 
concentration stocks, changing from tetrameric to monomeric  (Morgan et al., 2013a). 
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filtration was performed. Briefly, 0.5 ml sample of 0.1 mg/ml stock of each protein 
was incubated in PBS-CM at pH 7.4 at room temperature for 12 hr. The results show 
clearly that only M2PYK dissociated at 0.1 mg/ml. M1PYK, RPYK and LPYK 









Figure 3-24. Effects of DTT and H2O2 on the oligomerisation of M2PYK, RPYK and 
LPYK. Both enzymes were incubated at 0.1 mg/ml with or without 1mM DTT/1mM 
H2O2 in PBS-CM buffer at pH 7.4 at room temperature for 12 hours. Gel filtration 
traces of M2PYK show two distinct peaks corresponding to tetramer and monomer 
(Figure 2A). Curve of M2PYK with H2O2 shows a bigger monomer peak at about 1.6 
ml and curve of M2PYK with DTT shows a bigger tetramer peak around 1.33 ml. In 
both Figure B and C, LPYK and RPYK show a single peak at 1.33 ml, even with 1 
mM DTT or 1 mM H2O2. 
 
As shown in Figure 3-24, the ratio of tetramer to monomer is concentration dependent 
with higher concentrations favouring the tetrameric state. In this experiment, the time-
dependent dissociation of M2PYK was measured by diluting a solution of 20 mg/ml 
M2PYK to 0.1 mg/ml (PBS-CM, pH 7.4) and incubating for 0 h, 1 h, 2 h, 5.5 h, 8 h, 
and 12 h at room temperature. The results indicate that M2PYK dissociated slowly 
from tetramer to monomer reaching an equimolar equilibrium of 1 tetramer: monomers 
after ~8 h A similar experiment was carried out with the M1PYK isoform and showed 
no dissociation of the tetrameric form (Figure 2B). Gel filtration studies can only 
provide a reliable signal at relatively high protein concentrations greater than ~0.1 
mg/ml.  
Several papers have shown that the M2PYK tetramer has higher activity relative to its 
monomeric/dimeric forms (Ashizawa, McPhie, Lin, & Cheng, 1991; Chaneton et al., 
2012; Eigenbrodt et al., 1992; Mazurek, 2011). Here we show loss of enzyme activity 
correlates with the time dependent dissociation observed in the gel filtration 
experiments. (Figure 2C). In the enzyme assay (see methods) activities were measured 
using a stock solution of 20 mg/ml M2PYK which was diluted to a concentration of 
0.002 mg/ml in PBS-CM (pH 7.4). Monitoring enzyme activity as a function of time 
showed a 50% loss of activity of M2PYK in 30 min. The enzyme concentration used 
to measure the enzyme activity is 50 times more dilute than the solutions studied by 
gel filtration which explains the more rapid dissociation and loss of activity. In contrast, 
an identical study with M1PYK showed only 17% loss of M1PYK activity over the 3 
h period of the experiment consistent with M1PYK retaining its active tetrameric 
structure even at very low protein concentration. 
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3.4.5 Summary of results on the time dependent change in activity of hPYK  
From these series of assays, we could show that for M2PYK, LPYK, and RPYK 
protein, activity decrease gradually to nearly zero after dilution from high 
concentration stock to low concentration assay solution. Reducing reagents (DTT and 
TCEP) and the natural activator F-1,6-BP help to maintain protein activities in solution.  
We also could show that pre-incubation time at low protein concentration is an 
important parameter in enzyme activity measurement of PYKs, especially in M2PYK, 
LPYK and RPYK. 
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3.5 The effect of protein concentrations on pyruvate kinase activity  
Another parameter related to the dilution and pre-incubation time discussed above and 
that could affect the accuracy of enzyme activity measurement, is protein 
concentration. We studied LPYK at three concentrations. A series of time dependant 
assays were designed to find out how protein concentration affects rate of loss of 
activity after dilution. 
 
                             (a)                                                                      (b) 
 
                             (c)                                                                       
Figure 3-25. LPYK enzyme activity assay with pre-incubation of 0 minutes, 10 
minutes, 20 minutes. Assay conditions are 2mM ADP, 100mM KCl, 10mM MgCl2, 
in PBS-CM, pH 7.4, at room temperature. (a) protein concentration 0.001mg/ml, (b) 
protein concentration 0.002mg/ml (c) protein concentration 0.004mg/ml  
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From the above figure, it is apparent that time of incubation affects the lower 
concentration assays most with the largest drop in Vmax, shown in Figure 3-23. Kinase 
activity of LPYK in (a) showed wider gaps between the curves than in (b) and (c). To 
quantify this effect, we plotted the sub-saturating points of the three figures at 1.25 
mM PEP. 
LPYK



























Figure 3-26. LPYK time dependent assay when PEP concentration is at 1.25mM at 
0.001mg/ml, 0.002mg/ml, and 0.004mg/ml.  
 
From Figure 3-26, we see that lower protein concentration shows faster activity 
decrease rate. The decrease slope of activities is -3.3, -2.2, and -1.8 (UNITS) with 






CHAPTER 4. Activity regulation of human PYKs by 
natural metabolites 
4.1 Introduction 
4.1.1 Regulators of PYKs are diverse 
A variety of regulators of human PYKs has been discovered from small molecules to 
hormones and peptides, especially for M2PYK. For example, phosphotyrosine 
peptides bind directly to M2PYK and inhibit its enzyme activity. This has the effect 
of diverting  metabolic flux from energy production to anabolic processes (Christofk 
et al., 2008b). Another example is for LPYK which has been shown to be inhibited by 
alanine and ATP, which raises the Km and shifts the kinetics of PEP metabolism from 
hyperbolic to sigmoid (Llorente et al., 1970). Table 7 summarises published data on 
the wide range of metabolites known to either inhibit or activate the different 
mammalian PYK isoforms. 
Effector Classification Effect Effect mechanism Effect position Reference 
M1PYK  











DAPk protein-protein interaction 
activation of 
enzyme activity stabilise tetramer not shown 
(Mor et al., 
2012) 
MUC1-C protein-protein interaction 
activation of 
enzyme activity stabilise tetramer C474 
(Kosugi et al., 
2011) 
JMJD5 protein-protein interaction 
inhibition of 
enzyme activity promote dissociation of M2PYK 
tetramer 
interface 
(Wang et al., 
2014) 
phosphotyrosine protein-protein interaction 
inhibition of 






PML protein-protein interaction 
inhibition of 
enzyme activity promote dissociation of M2PYK not shown 
(Shimada et 
al., 2008) 
F16BP metabolite activation of enzyme activity 
promote association of M2PYK, 
stabilise R-state F-1,6-BP site 
(Dombrauckas 
et al., 2005) 
SAICAR metabolite activation of enzyme activity not shown 
not F-1,6-BP 
site 
(Keller et al., 
2012) 
serine metabolite activation of enzyme activity 






cysteine metabolite inhibition of enzyme activity promote dissociation of M2PYK not shown 
(Nakatsu et al., 
2015) 
phenylalanine metabolite inhibition of enzyme activity 




(Morgan et al., 
2013a) 
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ATP metabolite inhibition of enzyme activity not show active site  
T3 hormone inhibition of enzyme activity promote dissociation of M2PYK not shown 
(Morgan et al., 
2013a) 
LPYK  
F16BP metabolite activation of enzyme activity promote allosteric effect  F-1,6-BP site 
(Blair and 
Walker, 1984) 










F16BP metabolite activation of enzyme activity promote allosteric effect  F-1,6-BP site 
(Pinilla et al., 
1987) 
ATP metabolite inhibition of enzyme activity not show active site 
(Pinilla et al., 
1987) 
Ala metabolite inhibition of enzyme activity not show 
amino acid 
binding site 
(Marie et al., 
1980a) 
Table 7. Regulatory factors of PYK isoforms in vivo. (Effects of metabolites, 
protein-protein interaction, and hormone are highlighted by white, yellow, and blue, 
respectively) 
 
From this table, we see that F-1,6-BP is the natural activator of M2PYK, LPYK and 
RPYK and amino acids also play an important role in PYK regulation. As PYKs 
regulate the final step in the glycolytic pathway controlling the energy flux, it is 
reasonable to expect that metabolites in the pathway may up-or down-regulate the 
activity of this important final step. We therefore undertook a broad screen of some of 
the important metabolites to study their effect against all four human isoforms. 
4.1.2 Kinetic properties of the four human pyruvate kinase isoforms 
All assays were performed in 100mM KCl, 10mM MgCl2, pH 7.4, in PBS-cm, at room 
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Figure 4-1. Kinetics of M1PYK, M2PYK, LPYK and RPYK. Error bars are derived 
from three independent repeat experiments. 
 
(A)  and (C) The kinetic characterisations of the catalysis of PEP at saturating 
concentration of ADP (4mM). 
(B)  and (D) The kinetic characterisations of the catalysis of ADP at saturating 
concentration of PEP (10mM). 
 
		 LPYK	 RPYK M1PYK	 M2PYK	
Vmax 
µmol/min/mg 112.2 91.62 135.5 90.62 
Km[PEP] 1.07 0.44 0.13 0.55 
Km[ADP] 1.94 0.69 0.18 0.40 
 
Table 8. Kinetic properties of M1PYK, M2PYK, LPYK and RPYK 
 
M1PYK shows highest activity (Vmax = 135.5 µmol/min/mg), compared with M2PYK 
(Vmax = 90.62 µmol/min/mg), LPYK (Vmax = 112.2 µmol/min/mg), and RPYK (Vmax = 
91.62 µmol/min/mg). M1 also shows highest affinity for both PEP (Km = 0.13mM) 
and ADP (Km = 0.18mM), which are lower than data of M2PYK, LPYK and RPYK. 
These results correlate with previously published reports that M1PYK is a 
constitutively active enzyme compared with other isoforms (Morgan et al., 2013b). 
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4.1.3 Amino acids and metabolites screening 
An enzymatic assay was carried out to screen human pyruvate kinases and a search 
was made for enzymatic modulators. M1PYK, M2PYK, LPYK and RPYK were 
incubated for 10 minutes with 2 mM amino acids (including cysteine, histidine, 
tryptophan, glutamine, methionine, valine, serine, isoleucine, phenylalanine, alanine, 
proline, leucine, tyrosine, glycine, threonine, arginine, glutamic acid, and lysine), F-
1,6-BP and other metabolites (including F6P, malic acid, alpha-ketoglutarate, succinic 
acid, citric acid, GMP, AMP, UMP, oxalic acid). F-1,6-BP and oxalic acid were used 
as a positive control and negative control, respectively. The assay was performed in 
10 mM PBS at pH 7.4 at 37 ºC. Substrates were used at sub-saturating concentration 
at about Km (PEP) and Km (ADP) as shown in Chapter 5.1.1. The results of the screen 
are shown in this chapter in sections 4.2 and 4.5.  
4.2 M1PYK 
Regulatory effects of amino acids on the constitutively fully active M1PYK have been 
extensively studied (Carminatti et al., 1971, Consler et al., 1992, Cheng et al., 1996, 
Lonhienne et al., 2003, Lonhienne and Winzor, 2002, Williams et al., 2006, Herman 
and Lee, 2009, Urness et al., 2013). The results showed that only phenylalanine 
moderately regulates M1PYK by  inhibition of its enzymatic activity   (Carminatti et 
al., 1971). The other amino acids and metabolites did not show direct regulatory effects 
on M1PYK. In Chapter 3.2, it was also shown that natural allosteric activator F-1,6-
BP could not activate M1PYK much, as it is not an allosteric enzyme.  
M1PYK could be inhibited by the product analogue - oxalic acid. In the literature, 
phenylalanine and alanine are inhibitors of M1PYK (Williams et al., 2006) and they 
reported phenylalanine inhibited M1PYK by 20% but alanine didn’t show any 
inhibition effect on the activity of the protein. The inhibition ratios are not consistent 
with Carminatti and Williams’ data, probably because the concentration of Ala and 
Phe in their experiments were much higher.  As summarised in Figure 4-2, M1PYK 
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could not be regulated significantly by any of the amino acids or metabolites tested in 
the screen. 
 
Figure 4-2. Effect of metabolites on the activity of M1PYK activity. Error bars are 
derived from three independent repeat experiments. The protein concentration is 
0.01mg/ml. Buffer conditions are set as follow (sub saturating--substrate at about Km 
value): 10 mM PBS-CM, 0.55 mM PEP, 0.4 mM ADP, 100 mM KCl, 10 mM 
MgCl2, 37 ° C. 
4.3 M2PYK 
It has been reported that metabolites including activator serine (Chaneton et al., 2012), 
and inhibitors phenylalanine (Morgan et al., 2013a) and cysteine (Nakatsu et al., 2015) 
regulate M2PYK allosterically. F-1,6-BP is the natural activator of M2PYK 
(Dombrauckas et al., 2005).  
From the results shown in Figure 4-3, M2PYK is less active than M1PYK at sub-
saturating conditions (0.55mM PEP and 0.4 mM ADP). M2PYK enzyme activity (14 
unit/mg) was much less active compared with the activity of M1PYK (35 unit/mg). 
Natural activator F-1,6-BP activates M2PYK to 32 unit/mg, which is almost equal to 
the activity of fully active isoform M1PYK. Oxalic acid inhibits both M1PYK and 
M2PYK, providing a stable positive control inhibitor.  Surprisingly, not only amino 
acids like Ser, Phe, Cys, which have been reported previously, showed regulation of 
M2PYK, but we also found some additional activators and inhibitors from this screen. 
Gly, Ser, and His activate M2PYK from 14 unit/mg to 22 unit/mg, 30 unit/mg, and 31 
unit/mg respectively. The activation by Ser and His are as strong as the natural effector 
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F-1,6-BP. We also discovered a series of inhibitors (Val, Phe, Ala, Met, Thr, Iso, AMP, 
Pro, GMP, alpha-ketoglutarate, Cys). 
 
Figure 4-3. Effect of metabolites on activity of M1PYK and M2PYK. Error bars are 
derived from three independent repeat experiments. The protein concentration is 
0.01mg/ml. Buffer conditions are set as follow (sub saturating--substrate at about Km 
value): 10 mM PBS-CM, 0.55 mM PEP, 0.4 mM ADP, 100 mM KCl, 10 mM 
MgCl2, 37 ° C. 
In 2012, Chaneton’s research show that serine activates M2PYK by 11-fold (Chaneton 
et al., 2012). Our experiment, showed serine activates M2PYK 2-fold. This large 
difference between experimental results is probably due to different assay conditions 
and pre-incubation times resulting in different degrees of M2PYK dissociation from 
tetramers to monomers at the low concentrations required in the enzyme assays. This 
dissociation is highly PKM2-concentration-dependant and pre-incubation time 
dependant. Chaneton et al. used 4 nM M2PYK to incubate with ligand and further 
incubate for 20 minutes. But in our experiments, we used 126 nM M2PYK and 
incubated for 10 minutes. So, the protein will dissociate much faster in Chaneton’s 
assay than ours. Furthermore, in Chaneton et al.’s research (Chaneton et al., 2012), all 
other amino acids are weak activators like Ala and Phe, which according to our results 
are quite strong inhibitors. To further investigate the amino acids effect on M2PYK 
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and to study the possible opposing effect of activators and inhibitors of M2PYK, we 
tested a series of enzymatic assays by ligand competition. 
4.3.1 Opposing effects of amino acids on M2PYK are competitive 
In human cells, a range of amino acids are present at different concentrations. Both 
activators and inhibitors coexist in different tissues. It is therefore of interest to find 
out how ligands with opposing effects regulate M2PYK and whether this regulation 
could be physiologically important. 
4.3.1.1 The opposing effects of serine and alanine on M2PYK 
Briefly, the ligand competition assay was performed for the investigation of the effect 
on enzyme activity when both activator and inhibitor of M2PYK are present. Twenty-
five microliters of 0.004 mg/ml of protein in PBS was mixed and incubated with 
twenty-five microliters of both ligands (activator and inhibitor) at a given 
concentration with or without 1 mM DTT at 37 ºC at pH 7.4 for 10 minutes. The fifty 
microliters assay buffer (PBS_CM supplemented with 20 mM MgCl2, 200 mM KCl, 
1mM NADH, 40 U/ml LDH, as well as sub-saturating PEP (0.5mM) and ADP 
(0.4mM)) was added to each well to start the reaction and absorbance read at 340 nm 
on a multiplate reader. 
From the results shown in Figure 4-4 and Figure 4-5, 1.25 mM Ser activates M2PYK 
by about 10% and 100% with and without DTT respectively when Ala/Phe 
concentration is 0 mM. We also show in this experiment that the percentage of 
activation is also affected by reducing environment.  These results also suggested that 




Figure 4-4. Ligand competition of serine and alanine on M2PYK in the absence of 
DTT. Error bars are derived from three independent repeat experiments. 
 
The blue curve Figure 4-4 shows that activity of enzyme was reduced by alanine from 
about 16 unit/mg to 2 unit/mg with IC50 (alanine) of 45 µM. The enzyme was activated 
to 34 unit/mg in the presence of 1.25 mM serine.   
In a competition experiment in which both ligands are present at the same time, high 
concentrations of serine (1.25mM) increase the IC50 (alanine) by about 20 times to 837 
µM Figure 4-5.   
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Figure 4-5. Ligand competition of serine and alanine on M2PYK in the presence of 1 
mM DTT. Error bars are derived from three independent repeat experiments. 
 
In the presence of DTT, activity of enzyme without alanine or serine increases to 32 
unit/mg compared with enzyme without DTT (Figure 4-7). M2PYK with 1.25mM 
serine was activated to 37 unit/mg from 33 unit/mg. The IC50 (alanine) at each 
concentration of serine was doubled in the presence of DTT compared with Figure 4-
4, which also suggested that DTT decreases the affinity of alanine. 
 
 
Figure 4-6. Ligand competition of serine and phenylalanine on M2PYK in the 
presence of 1 mM DTT. Error bars are derived from three independent repeat 
experiments. 
 
The blue curve in Figure 4-6 shows that phenylalanine inhibits enzyme activity from 
14 unit/mg to almost zero (at a concentration of 4mM). The yellow curve suggests that 
serine activates enzyme to 37 unit/mg. The IC50 (phenylalanine) increased by about 20 






Figure 4-7. Ligand competition of serine and phenylalanine on M2PYK in the 
absence of DTT. Error bars are derived from three independent repeat experiments. 
 
In the presence of DTT, activity of enzyme without phenylalanine or serine increases 
to 29 unit/mg compared with enzyme without DTT (Figure 4-9). M2PYK with 
1.25mM serine was activated to 35 unit/mg. The IC50 (phenylalanine) was increased 
by 8 times in the presence of DTT and in the absence of serine, which also suggested 
that DTT decreases the affinity of phenylalanine. 
 
In summary, different concentrations of binary mixtures of serine and alanine (or 
phenylalanine) were used to show their competing effects on enzyme activity. At a 
concentration of 1250 µM, serine increases the IC50 values of inhibitory amino acids 
alanine (from 124 µM to 1536 µM) and phenylalanine (from 410 µM to 2922 µM). 
The measured concentrations of amino acids in normal and cancer tissues is in the high 
micromolar to low millimolar range (Lefauconnier et al., 1976, Brodzki et al., 2005). 
With an approximate cellular concentration of alanine of 1 mM, M2PYK is only ~10% 
active, however in the presence of serine at an intracellular concentration of ~0.6 mM, 
activity is restored to ~65%. A similar effect has been measured for phenylalanine 
which at a cellular concentration of ~0.2 mM reduces M2PYK activity to ~ 65% which 
can be raised to nearly full activity in the presence of 0.6 mM serine. 
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4.3.1.2 .The effects of histidine/glycine and alanine on M2PYK 
Opposing effects of histidine and alanine (-DTT)
















































Figure 4-8. Ligand competition of histidine and alanine on M2PYK in the absence of 
DTT. Error bars are derived from three independent repeat experiments. 
 
Histidine activated the enzyme from 15 unit/mg to 28 unit/mg in the absence of alanine. 
Alanine inhibited the activity from 15 unit/mg to near zero. But, IC50 (alanine) did not 
increase significantly when higher concentrations of histidine were added. 
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Figure 4-9. Ligand competition of histidine and alanine on M2PYK in the presence 
of 1 mM DTT. Error bars are derived from three independent repeat experiments. 
 
Interestingly, in the presence of 1 mM DTT, histidine could no longer activate M2PYK  
at any concentration. 
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Figure 4-10. Ligand competition of glycine and alanine on M2PYK in the absence of 
DTT. Error bars are derived from three independent repeat experiments. 
 
Glycine activated the enzyme from 13 unit/mg to 27 unit/mg in the absence of alanine. 
Alanine inhibited the activity from 13 unit/mg to near zero. As with histidine, the IC50 
(alanine) did not increase when higher concentration of glycine was added. 
Ala/Gly














































Figure 4-11. Ligand competition of glycine and alanine on M2PYK in the presence 
of 1 mM DTT. Error bars are derived from three independent repeat experiments. 
 
As with His, in the presence of 1 mM DTT, Gly could no longer activate the activity 
of M2 at any given concentration. IC50 of Ala remained at the same level but 50% 
higher than M2PYK without DTT. The results from Figure 4-8, Figure 4-9, Figure 
4-10, and Figure 4-11  can be summarised as follows:   
1. Both His and Gly activate M2PYK on their own 
2. Neither Gly nor His significantly increases the IC50 of alanine. This result is in 
contrast with the effect of Ser which also activates M2PYK on its own but 
decreases affinity of Ala and Phe.  
3. DTT decreases the affinity of Ala (and increases the IC50). 
4. IC50 (Ala) is around 40 µM without DTT and 70 µM with DTT even when His 
or Gly were added at any given concentration. 
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4.3.1.3 Conclusion and discussion: 
From these experiments, we can conclude two points. Firstly, we have generated 
strong evidence showing that activator and inhibitor amino acids bind competitively. 
Furthermore, given that serine increases the affinity of alanine but glycine and 
histidine do not, we suggest that this regulation may stem from two different 
mechanisms, which are likely to be important in cellular regulation.  
The cellular concentration of alanine and serine (Table 2 Chapter 1) was reported at 
0.5 mM and 0.6 mM respectively in normal cells (Iovine et al., 2014). The 
concentration increased to 5.7 mM (alanine) and 1.5 mM (serine) in cancer cells 
(Brodzki et al., 2005). From Figure 4-4, we see the activities of M2PYK under these 
two conditions are about 25 unit/mg and 8 unit/mg, respectively.  We have also shown 
that the amino acid modulation of M2PYK activity is redox-dependent. In other words, 
reducing environments de-sensitise M2PYK to amino acid inhibition/activation, and 
vice versa. This observation is particularly interesting for cancer cells because the 
redox homoeostasis of cancer cells is deregulated.   
 
4.4 LPYK 
4.4.1 Amino acids and metabolites screening 
In the current literature, only F-1,6-BP and alanine have been reported as regulating 
LPYK (Llorente et al., 1970). In experiments reported in this thesis we tested 18 amino 
acids and 10 metabolites to see if LPYK could be regulated. M1PYK was included for 
comparison. Experimental conditions are described in Chapter 4.1.3. All enzyme 
activity assays were carried out with a protein concentration at 0.01mg/ml. Buffer 
conditions are set as follow: 10 mM PBS-CM, 0.55 mM PEP, 0.4 mM ADP, 100 mM 
KCl, 10 mM MgCl2, 37 ° C. 
From the results in Figure 4-12 the specific activity of LPYK is 17 unit/mg. F-1,6-BP 
is a natural activator of LPYK which activated LPYK to 31 unit/mg. Oxalic acid is a 
natural inhibitor of LPYK which inhibited the protein to 4 unit/mg. In contrast to these 
positive and negative controls, none of the amino acids and metabolites were found to 
have a significant effect on the enzyme activity of LPYK. From our enzyme assay we 
found that alanine at 2 mM did not show any change of activity to LPYK. This differs 
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from the Llorente results that showed inhibition of LPYK (50% inhibition by 0.1 mM 
alanine) (Llorente et al., 1970). The LPYK that Llorente paper used is from mouse 
liver cells extract, therefore it could be that the mouse LPYK has different activity than 
our recombinant human LPYK because of post translational modifications. Also, the 
mouse liver cells extract could contain other PYK isoforms which we have shown are 
significantly down regulated by alanine.   
Initially we hypothesized that cysteine is a reducing agent that could activate LPYK 
like DTT. Surprisingly, the enzyme data showed that cysteine has no activation nor 
inhibition to LPYK. 
 
Figure 4-12. Effects of metabolites on activity of LPYK. Error bars are derived from 
three independent repeat experiments. The protein concentration is 0.01mg/ml. Buffer 
conditions are set as follow: 10 mM PBS-CM, 0.55 mM PEP, 0.4 mM ADP, 100 mM 
KCl, 10 Mm MgCl2, 37 ° C. 
 
The enzyme activity of LPYK in Figure 4-12 was not regulated by 2 mM cysteine. 
However, from the TDA result in Figure 4-13 10 mM cysteine showed an increase in 


































































































































































Figure 4-13. (A) Raw data of TDA for LPYK incubated with 0.1 mM, 1 mM and 10 
mM Cys. (B) Derivative calculations of the fluorescence readings.  
 
4.4.2 T3 is an inhibitor of LPYK 
T3 (triiodothyronine) is a hormone in human that is responsible for the regulation of 
metabolism. From  Morgan’s paper (Iovine et al.2014). T3 was found to be a strong 
inhibitor of M2 PYK (Morgan et al., 2013b). To confirm if T3 can also inhibit LPYK 
an enzymic assay was performed with addition of 20µM T3. The results showed that 
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Previous studies showed that T3 inhibited M2PYK thereby increasing cell 
proliferation (Morgan et al., 2013b). Therefore, inhibition of LPYK shown here 
suggests that T3 may also play a role in the regulation of LPYK in cells. 
 
Figure 4-14. Structure of triiodothyronine (T3). 
LPYK vs T3































Figure 4-15. LPYK was diluted to 0.001mg/ml from 16.1mg/ml in to PBS solution 
and PBS solution with 20µM T3. After 10 minutes room temperature pre-incubation, 
the Vmax of RPYK with T3 was reduced from 121.2 unit/mg to 61.23 unit/mg. 
4.5 RPYK 
In the published reports, from all metabolites tested only alanine has been reported as 
an inhibitor of RPYK (Marie et al., 1980b). But surprisingly, we show that alanine is 
a strong activator for RPYK in the assays used in this thesis. This difference may be 
because the protein used in Marie’s assays was extracted from human red cells and 
may be modified (e.g. phosphorylated) or be bound to other contaminant metabolites.   
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As summarised in Figure 4-16, our single-point assay showed that RPYK was 
upregulated by natural activator F-1,6-BP and down regulated by natural inhibitor 
oxalic acid.  Eleven amino acids, further investigated in 4.5.1, enhance RPYK activity 
by between 1.5-fold and 2-fold. 
 
 
Figure 4-16. Effect of metabolites on activity of RPYK. Error bars are derived from 
three independent repeat experiments. The protein concentration is 0.01mg/ml. Buffer 
conditions are set as follow: 10 mM PBS-CM, 0.55 mM PEP, 0.4 mM ADP, 100 mM 
KCl, 10 mM MgCl2, 37 ° C. 
 
4.5.1 11 amino acids up-regulate RPYK 
Interestingly, unlike M2PYK, there is no inhibitor of RPYK found among all the 
amino acids and metabolites tested, but we have identified several activators. Here we 
carried out dose response curves on all the activators to investigate the AC50. The assay 
details are given in section 5.4.2. The results summarised in Figure 4-17 show that 10 
amino acids activate RPYK. Interestingly, cysteine is an activator under 1mM 






















































































































































































Figure 4-17. Effects of amino acids on enzyme activity of RPYK. Error bars are 
derived from three independent repeat experiments. The protein concentration is 
0.01mg/ml. Buffer conditions are set as follow: 10 mM PBS-CM, 1 mM ADP, 100 
mM KCl, 10 mM MgCl2, 37 ° C. 
 
4.5.2 Amino acids influence thermal stability of RPYK 
To confirm that the amino acids were binding to RPYK, we investigated amino acid 
influence on the thermostability of RPYK. Results for histidine (which gives the 
strongest activating effect on RPYK) thermal stability are shown in Figure 4-18. 
Addition of 0.1mM, 1mM, or 10mM histidine increases the melting temperature from 
62 ºC (unliganded) to 64 ºC, 64 ºC and 64 ºC, respectively.  This correlates with the 
effect found in the enzyme activity assay in which RPYK activity increases from about 
16 unit/mg (0 mM His) to 25 unit/mg (1 mM His) over the same concentration range 
(Figure 4-17). 















Figure 4-18. Thermal stability of RPYK and effects of His at 0.1mM, 1mM, 10mM. 
Interestingly, the melting temperature of RPYK increased from 62 ºC (RPYK) to 64 
ºC (RPYK+His at 0.1mM, 1mM, 10mM). 
4.5.3 T3 is an inhibitor of RPYK 
T3 (triiodothyronine) is a thyroid hormone produced by thyroid gland in human body 
that is responsible for the regulation of metabolism. The inhibition of M2PYK activity 
by T3 has been reported (Morgan et al., 2013b). The inhibition of LPYK has been 
discussed previously (see Figure 4-15).  We also carried out an assay to test the 
possible inhibition of RPYK by T3 and show (Figure 4-19) that RPYK activity was 
inhibited by 85% from 98.34 unit/mg. As with LPYK, we did not show the dose 
response curve of T3, because the solubility of T3 in aqueous buffer was low and the 
results were complicated. 
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RPYK vs T3

































Figure 4-19. The T3 effect on RPYK. RPYK was diluted to 0.001mg/ml from 
8.1mg/ml in to PBS solution and PBS solution with 20uM T3. After 10 minutes room 
temperature pre-incubation, the Vmax of LPYK with T3 was reduced from 98.34 
unit/mg to 12.88 unit/mg. 
4.6 Discussion 
4.6.1 Amino acids and metabolites screening 
In this study, we screened a group of amino acids and metabolites and determined the 
specific activities of each PYK isoform and ligand combination (at a ligand 
concentration of 2 mM). Here we combine these results to calculate the relative 
activation or inhibition percentage in Error! Reference source not found., using the 
following formula with M2PYK with F-1,6-BP as an example: 
 
 From this table, we can conclude that M1PYK and LPYK are not very sensitive to 
amino acids and metabolite regulation. In contrast, M2PYK and RPYK are sensitive 
to amino acids and metabolites regulation, but in different ways. There are both 
activators and inhibitors for M2PYK, but only activators for RPYK except at high 
concentrations of cysteine. 
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Table 9. Summary of metabolites screening of four human PYK isoforms. Strong 
activation or inhibition was marked with red and green (more than 20%). 
 
M2PYK is critical for regulating the synthesis and metabolism of serine. Knock-down 
and inactivation of M1 and M2 PYK have been shown to result in a build-up of 
metabolites in the glycolytic pathway enabling synthesis of serine from its precursor 
3-phosphoglycerate (Chaneton et al., 2012). In a complementary experiment, cells 
treated with a synthetic M2PYK activator become dependent on serine for continued 
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cell proliferation (Kung et al., 2012). Together with the knowledge that binding of 
serine activates M2PYK, these results suggested that there is a feedback mechanism 
regulated by serine concentration, which provides a balance between glycolysis/ATP 
production (promoted by serine-bound active M2PYK) and cell proliferation 
(favoured by inactive M2PYK). A number of families of drug-like M2PYK activator 
molecules have been tested on cancer cell lines (Anastasiou et al., 2012; C. Guo et al., 
2013; J. K. Jiang et al., 2010; Kung et al., 2012; Vander Heiden, Christofk, et al., 2010; 
Yacovan et al., 2012). Interestingly, M2PYK activators profoundly reduced cell 
proliferation only in models where nonessential amino acids (alanine, aspartic acid, 
asparagine, glutamic acid and serine) are removed from cell media (Kim et al., 2015; 
Kung et al., 2012; Parnell et al., 2013; Warner, Carpenter, & Bearss, 2014). This 
sensitivity is likely due to a lack of serine nutrient which cannot be synthesised by the 
cell when M2PYK is activated. 
 
Figure 4-20. Intracellular concentrations of free amino acids in normal and tumour 
tissues. The concentration ranges of detected amino acids from two references 
(Brodzki, Tatara, Pasternak, Rózańska, & Szponder, 2005; Lefauconnier, Portemer, 
& Chatagner, 1976). 
 
As shown in Figure 4-20, measured intracellular alanine concentrations from various 
cell types range from 0.4 mM to over 6.8 mM in Brodzki’s study, which is in the range 
to inhibit M2PYK activity in vitro. However, in vivo the regulation depends not on a 
single ligand but on the combination effect of all regulators including the strong 
activator F-1,6-BP with low AC50. The main biosynthetic route for alanine is via 
alanine transaminase (ALT) using pyruvate as a substrate (Chougule et al., 2008) and 
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elevated levels of ALT are indeed found in cancer patients. Pancreatic ductal 
adenocarcinoma tumour cells rely on alanine which is provided in millimolar 
concentrations by autophagous pancreatic stellate cells which feeds the tumour (Sousa 
et al., 2016). Labelling studies further show that pyruvate generated from the 
transaminase feeds the citric acid cycle. These observations suggest that alanine serves 
a double purpose of blocking glycolytic flux (allowing metabolite to build up the 
concentration of the PYK activator F-1,6-BP) and providing pyruvate for the TCA 
cycle. 
Allostasis is the process of achieving equilibrium in a changing (nutrient) environment, 
and M2PYK provides an excellent example of an allostatic regulator in which the 
opposing effects of activating (alanine) and inhibiting (serine) amino acids provide a 
finely-balanced feed-back mechanism for tuning M2PYK activity over a wide range 
of absolute and relative concentrations. With high levels of serine (or F-1,6-BP), 
M2PYK will be turned on and the TCA cycle will be fuelled by pyruvate from the last 
step in glycolysis (Chaneton et al., 2012). With high levels of alanine (or phenylalanine 
or tryptophan), M2PYK is turned off and the TCA cycle may be fuelled by pyruvate 
produced by alanine transaminase (Sousa et al., 2016). Depending on the relative 
concentrations of serine (up to ~1 mM) and alanine (up to ~5 mM), M2PYK activity 
can be tuned to run from 5% to 100% of its maximum velocity Figure 4-4. The 
important regulatory factor is the ratio of activating and inhibiting 8 amino acids and 
other effectors such as F-1,6-BP, as well as post-translational modifications. Thus, 
M2PYK can act to regulate metabolism by sensing a range of concentrations and can 
use these inputs to control its enzyme activity by switching quickly (within seconds) 
between inactive T-state and active R-state conformations. At very low levels of amino 
acid concentration (less than their Ki values) and with enzyme concentration less than 
~2 µM, M2PYK will dissociate into enzymatically inactive monomers. Monomeric 
M2PYK has been shown to enter the nucleus and promote transactivation of HIF-1 
target genes (Lv et al., 2013), many of which are metabolic enzymes, thus providing 
another regulatory mechanism for M2PYK. Cellular biochemical networks that 
regulate metabolism, phagocytosis and transcription are composed of highly 
interconnected nodes which communicate by perturbing molecular concentrations and 
reaction rates. The structural and enzymatic results presented here provide a molecular 
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description of the M2PYK metabolic sensor mechanism which can react to widely 
fluctuating nutrient concentrations in the cell and deliver appropriate signal outputs to 
these biochemical pathways.  RPYK, LPYK, and M1PYK are expressed in specific 
tissues which may go some way to explaining why their regulation by amino acids is 
different to that of M2PYK.  
For LPYK and M1PYK, both enzymes are quite insensitive to amino acids 
concentration. The reason might be that their environments (in muscle and liver) are 
stable and are constantly exposed to higher metabolites concentrations. T3 regulates 
LPYK and RPYK 
In 2013, T3 was reported to be strong inhibitor of M2PYK by stabilising an inactive 
monomeric form of M2PYK. Here we showed that T3 can also strongly inhibit LPYK 
and RPYK. M1PYK was also reported to be inhibited by T3 with an IC50 above 4 µM. 
However, from the analytical gel filtration results in section 2.4.2, M1PYK, LPYK, 
and RPYK do not dissociate at 0.1 mg/mg, which is the lowest concentration we could 
use in the size exclusion chromatography. We cannot confirm if the inhibition of 
LPYK and RPYK by T3 is caused by similar mechanism as M2PYK. 
In future work, several possible experiments could further explore this inhibitory 
mechanism. For example, analytical gel filtration of LPYK and RPYK with T3 might 
show if T3 stabilises the monomeric form of both isoforms. Co-crystallisation of 
M2PYK, LPYK, and RPYK in complex with T3 would also be good targets and show 






CHAPTER 5. Biophysical assays on human pyruvate 
kinase isoforms 
Introduction 
In this chapter, we describe the use of NMR to study ligand binding by the different 
human isoforms of PYK. In Chapter 3, enzymatic studies were used to measure the 
inhibition and activation of metabolites of all four isoforms and these results were 
consistent with amino acids binding in an allosteric pocket and activating or inhibiting 
the M2PYK isoform. RPYK also showed enzymatic activation by 11 of the 20 amino 
acids tested. The NMR experiments described here show that even isoforms, for which 
metabolites have little inhibitory or activating effect, can also bind strongly to the 
conserved allosteric pocket. 
5.1 STD-NMR assay for ligands binding 
Nuclear magnetic resonance (NMR) is an excellent method for detecting ligand- 
protein binding directly. Saturation Transfer Difference nuclear magnetic resonance 
(STD-NMR) spectroscopy provides us with a powerful tool to monitor weak ligand- 
protein binding for KD values in the mM to µM range (Venkitakrishnan, Benard, Max, 
Markley, & Assadi-Porter, 2012). As the name indicates, STD-NMR measures the 
NMR signal of the magnetization transferred from protein (the receptor) to the bound 
ligand. A selective radiofrequency radiation is applied to saturate protein NMR signals. 
Then, this saturation transfers to small ligands bound to the protein by intermolecular 
NOE (Nuclear Overhauser Effect) (Anderson & Freeman, 1962). The magnitude of 
such saturation transferred to the small molecule is related to the proximity of ligand 
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atoms to the protein binding pocket (Mayer & Meyer, 2001).
 
Figure 5-1. Basic theory of STD-NMR. I0: signal intensities of the free ligand. Isat: 
signal intensities of bound ligands. ISTD: signal intensities of bound ligands. The 
difference spectra show which signals have been affected by binding to the receptor. 
The size of the signal is proportional to the proximity of the ligand atom to the protein. 
The figure shows the basic theory of STD-NMR: the STD spectrum ISTD is the 
difference between an off-resonance ligand reference proton spectra I0 and an on-
resonance ligand spectra Isat after irradiating the protein only at a specific range. For a 
ligand bound to the protein, its protons which are close to the protein (less than 5 Å) 
receive saturation transfer from the protein and appear in the difference in spectra. The 
protons which are closer to the protein will show stronger signals in the ISTD spectra. 
As with all NOEs, the magnetization transferred from protein to ligand obeys an 
Figure	from	http://www.glycopedia.eu/ 
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inverse power law and is proportional to 1/d**6. In the STD spectra, only signals from 
hydrogen atoms from the ligand which are in close proximity to the protein will show 
up, as only for these atoms is there a difference between the on-resonance and off-
resonance spectra.  The differences in the NMR intensities are shown in the difference 
spectra: ISTD = I0 - Isat where ISTD shows intensity of the binding. 
The intensity of all NMR signals depends on the ‘saturation time’ which in these 
experiments can vary between 5 and 15 s. All results presented here were measured 
with a saturation time of 16 seconds. For a given saturation time an amplification factor 
can be determined and used to scale results from different experiments.   If we choose 
one proton peak as a standard, the amplification factor (Astd) can be calculated from 
the equation below.  
The STD amplification factor (Astd): Astd is determined by the relative STD effect 
!"#$
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 and the molar ratio of ligand to protein ['])
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.   The average number of ligand 
molecules saturated per molecule of receptor. These Astd values for each peak in the 









ISTD: is the signal intensity of a given peak of a bound ligand. 
I0: a given peak of signal intensities of the peak in the non-resonance spectrum, which 
is at the same position as the chosen ISTD peak   
[L]T: ligand concentration.  
[P]: total protein concentration in the solution.   
Protons which are closer to the receptor show higher +,-. values than other protons. 
At a given saturation time and ligand concentration, the amplification factor also could 
be depicted as the average number of small molecules that bind to one molecule of 
protein. 
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Mapping of the ligand binding moieties: These differences in Astd values can be used 
for ‘Ligand Mapping’ helping to identify which ligand moieties are important and bind 
closer to protein. If we set the peak in the STD spectra with highest intensity of ligand 
hydrogens to 100%, and calculate the percentage of all other hydrogen signals, a ligand 
binding moieties map may be generated. An illustration of binding mapping for a 
ligand shows the process of fast exchange between the pocket on the target protein and 
the ligand in Figure 5-2. The protein receives the selective saturation pulse and 
transfers the magnetization signal to hydrogen atoms on bound small ligand molecules. 
Protons, which are in close contact with the pocket, receive higher saturation signal. 
More remote ligand hydrogens receive less saturation. Atoms not in contact with the 
receptor at all do not receive a saturation signal. The mapping of ligand binding 
moieties reflects that the different proximities of each group on the ligand to the 
receptor surface. 
 
Figure 5-2. Illustration of how saturation may be transferred to a specific ligand. 
Larger-sized symbols represents a closer interaction with the target protein. 
Determination of dissociation constant (KD): KD may also be measured by STD-
NMR by titrating increasing ligand concentrations. An equation analogous to the 





 Equation 5-2, the Michaelis-Menten equation. 
Where [L] = ligand concentration. 
Vmax = maximum rate reached in the enzyme reaction system. 




 Equation 5-3 the analogous equation.  
Where aHIJ	is the maximum amplification factor. 
[L] = ligand concentration. 
KD = the substrate concentration at half Vmax point. 
In this equation, when ligand concentration [L] is increasing, the ligand-protein 
binding will be saturated and the amplification +,-. will increase until it reaches the 
maximum value aHIJ	(assuming that the ligand concentration is much higher than 
protein concentration ([L] >> [P])). The +,-. here can be any given peak in the STD-
NMR spectrum. 
5.2 Protocol and results 
A 1D proton NMR (DPFGSE-Double Pulse Field Gradient Spin Echo) measurement 
on the protein-ligand mixture was carried out to measure the ligand spectra just before 
the STD-NMR measurement to determine the purity of the ligand solution. As the 
STD-NMR samples were prepared in 90% H2O and 10% D2O solution to investigate 
exchangeable protons, the concentration of small ligands is typically between 0.1 and1 
mM, but water has a concentration of 55 M and the assay suffers from the H2O signal 
masking all the other small ligand signals. To overcome this, a water suppression pulse 
sequence was used in these NMR assays. 
Samples for NMR analysis were prepared in PBS with metals [66.7 mM KCl, 6.7 mM 
MgCl2] containing 20 µM PYK (M1, M2, L, or R), 1 mM amino acid (His, Phe, Ala, 
Ser, or Cys), 80 mM potassium phosphate, 10 % D2O at pH 7.4. 550 µl of the sample 
was placed into a Norell NMR tube (5 mm o.d). 1D NMR data were recorded at 25 ºC 
with a Bruker Advance 600 NMR spectrometer 10 minutes after adding 1 mM amino-
acid ligand. All the data were processed using NMR data processing software-TopSpin 
3.5pl 6. 
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The spectra for LPYK in complex with each of the ligands (1 mM L-serine, L-
phenylalanine, L-histidine, L-cysteine, or L-alanine) are shown in Figure 5-3. There 
are some similar peaks at around 4.7 ppm and 3.5 ppm in all the spectra. Peaks at 
around 4.7 ppm are signals of hydrogen in water and peaks at around 3.5 ppm are 
assumed to be hydrogen in glycerol. The appearance of glycerol in the spectra was 
unexpected and we hypothesized that the glycerol was probably introduced during the 
protein purification step. This may explain the same peaks present at around 3.5 ppm 
in all the spectra. All the other peaks from each spectrum can be assigned to hydrogens 














Figure 5-3. 1H NMR spectra for L-phenylalanine, L-cysteine, L-histidine, L-serine, 
and L-alanine. The upper part of each figure is a standard spectrum from the Biological 
Magnetic Resonance Data Bank (http://www.bmrb.wisc.edu/ref_info/statful.htm) and 
the bottom part is the 1D protein NMR spectrum of the protein-ligand (LPYK-amino 
acids). Peaks of hydrogen atoms bonded to Ca and Cb have been assigned for each 
amino acid. a) LPYK-cysteine; b) LPYK-alanine; c) LPYK-histidine; d) LPYK-
phenylalanine; e) LPYK-serine. 
On-resonance spectra were obtained in Bruker Advance III by saturating the protein 
with a set of Gaussian-shaped pulses (saturation time 3 s, 50 ms for each pulse at 20 
Hz) at -2 ppm, where the ligands do not have signals but the protein has. Off-resonance 
irradiation is set at around 50 ppm to obtain the ligand reference spectra. Data were 
collected through standard Bruker pulse programs at 25 °C. As shown in Figure 5-4, 
the spectrum in green is the ligand reference spectrum I0, which contains the signals 
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of all ligands including ligands bound to LPYK and ligands not bound to protein. The 
spectrum in red is Isat, which is the on-resonance spectrum containing only signals of 
ligand not bound to LPYK. The difference spectrum of ISTD (blue) between spectra of 
I0 (Greenhall) and Isat (red) has been processed in NMR data processing software-
TopSpin 3.5pl 6. The ISTD spectrum is scaled up by 61.02-fold as the difference 
between I0 and ISTD is relatively small. These three spectra show similar peaks at 
around 3.7 ppm, 1.4 ppm. This result suggests that these spectra could be consistent 
with signals of hydrogen from alanine however, some peaks were detected which do 
not exist in Figure 5-3 b, so alanine can be discounted. Peaks at around 4.7 ppm in the 
three spectra are believed to be signals from water and peaks at around 3.5 ppm only 
in I0 and ISTD are estimated to be signals of contaminants.  
 
 
Figure 5-4. On-resonance spectrum ISAT, Off-resonance irradiation I0, and difference 
spectrum of LPYK-alanine mixture. 
5.2.1 STD-NMR of M1PYK, M2PYK, LPYK, and RPYK with Phe 
NMR measurements for M1PYK with 1 mM Phe, M2PYK with 1 mM Phe and RPYK 
with 1 mM Phe and LPYK with 1 mM Phe were processed using same method 
described above and the results are shown in Figure 5-5. From this figure, three peaks 
at about 7 ppm show signals for Phe. Water molecules, which bind to the protein, also 
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show signals in the STD-NMR spectra and peaks around 4.7 ppm suggests that 
hydrogen from water are saturated by association with the protein. The signal of 1H on 
Ca and 1H Cb of Phe have been pointed out in Figure 5-3. There are peaks in the spectra 
of M1PYK and M2PYK with Phe at 3.5 ppm in Figure 5-5, which are again from the 
contaminant.  
 
Figure 5-5. Comparison of peak intensities in the STD-NMR spectra. Purple curve 
represents STD-NMR spectrum of 20 µM RPYK with 1mM Phe; Green represents 
M1PYK; Red represents LPYK; Blue represents M2PYK.  
 
To further analyse and compare the spectra between M1PYK-Phe, M2PYK-Phe, 
LPYK-Phe, and RPYK-Phe, we calculated the amplification factors of each peak on 







We chose the phenyl group peaks, which show the strongest signals in the STD-NMR 
data. The ASTD value of the phenyl group peaks are shown in Figure 5-6. The 
154 
amplification factor from the M1PYK-Phe spectrum is about 0.8. The amplification 
factors from the other three spectra are about 0.5. As ligand concentration and 
saturation time were the same in these four experiments and ASTD (M1PYK) > ASTD 
(M2PYK) > ASTD (LPYK) > ASTD (RPYK), it suggests the average number of Phe 
molecules binding to one M1PYK, M2PYK, LPYK, or RPYK molecule (monomer) 
are about 0.8, 0.4, 0.5, or 0.6, respectively. It also suggests that the affinity of M1PYK 
for Phe is higher than that of the other three isoforms. Interestingly, from our studies 
of amino acid regulation of enzymatic activity in Chapter 4, Phe enhances the activity 
of RPYK, exerts strong down-regulation on M2PYK, slight down-regulation on 
M1PYK, and has no effect on LPYK. This suggests that though the amino acids 
pockets in four isoforms are very conserved, the effects caused by amino acid binding 
are different. 
 
Figure 5-6. The Amplification factors of 1H on the phenyl group of STD-NMR 
spectra. 
 
To compare signals of hydrogen on different position of Phe, we calculated the 
amplification factor of all six peaks of all four human PYK isoform spectra in Figure 
5-5. We set the highest amplification factor in each spectrum as 100% and calculated 
the relative percentage of other hydrogen amplification factors. The results are shown 
in Figure 5-7. From these mappings, hydrogens with the highest amplification factor 
are on the phenyl group in all four isoforms. Hydrogens on Cb show the lowest 
amplification factor. This kind of trend suggests that the phenyl group might be closer 















Figure 5-7. Mapping of ligand binding moieties of Phe in the STD-NMR spectra of all 
four human PYKs with Phe. H(A)-H(B)represent hydrogens on different position of 
Phe. 
5.2.2 STD-NMR of M1PYK, M2PYK, LPYK, and RPYK with Ala 
We processed the data to get the difference spectra (ISTD) of four STD-NMR 
measurements of hPYKs with 1 mM Ala. The results are shown in Figure 5-8. All four 
spectra of M1PYK with Ala, M2PYK with Ala, LPYK with Ala, and RPYK with Ala 
show peaks at 3.7 ppm and 1.4 ppm, which are same as peaks as in Figure 5-3. This 
result suggests that Ala binds to all human PYK isoforms. There are still peaks at 
around 3.5 ppm, which is estimated as signal from contaminating glycerol introduced 
in the purification step. 
 
Figure 5-8. Comparison of peak intensities in the 1H NMR spectra of Ala with human 
pyruvate kinases (Peaks in blue indicate Ala with M1PYK, M2PYK in red, LPYK in 
green, RPYK in purple).  
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To further investigate the binding affinities of four isoforms with Ala, we chose the 
amplification factors of the peak of hydrogen on Cb of Ala at 1.4 ppm to compare in 
Figure 5-8. Interestingly, this result shows the same trend as in the Phe assays in Figure 
5-6. M1PYK shows highest amplification factor and it suggests that the affinity of Ala 
with M1PYK is higher than Ala with other isoforms. This also suggests that the 
average occupancy of Ala bound to each monomer of M1PYK is about 1, but that the 
occupancy of M2PYK monomer is just 0.5. Compared with the kinetic data of these 
enzymes in Chapter 4, only M2PYK and RPYK could be regulated by alanine. This 
again suggests that that alanine binds to the conserved amino acid binding pocket in 




Figure 5-9. The Amplification factors of 1H on Cb of Ala determined from STD-NMR 
spectra. 
The mapping of ligand binding moieties of alanine in Figure 5-9 shows that the 















Ca in all four isoform assays.  This result might suggest that alanine binds to the same 
pocket of four isoforms. 
 
Figure 5-10. The mapping of ligand binding moieties of alanine in the STD-NMR 
spectra of all four human PYK isomers. H(A)-H(B) represent hydrogens on Calpha and 
Cbeta. 
5.2.3 STD-NMR of M1PYK, M2PYK, LPYK, and RPYK with Cys 
We processed the data to get the difference spectra (ISTD) for four STD-NMR 
measurements of hPYKs with 1 mM Cys. The results are shown in Figure 5-11. All four 
spectra contain peaks at around 3 ppm and 4 ppm, which are the same as peaks in 
Figure 5-3.  As with Ala and Phe measurements, Cys STD-NMR results suggest that 




Figure 5-11. Comparison of peak intensities in the 1H NMR spectra of Cys with human 
pyruvate kinases (M1PYK in purple, M2PYK in green, LPYK in red, and RPYK in 
blue). 
 
To further investigate the binding affinities of four isoforms with Cys, we chose the 
amplification factors using a signal from a hydrogen atom on Cb of Ala which occurs 
at 3 ppm in Figure 5-11. Again, this result shows same trend as for Phe and Ala (Figure 
5-6 and Figure 5-9). M2PYK shows a much lower amplification factor and it suggests 
that the affinity of Cys with M2PYK is weaker than Cys with other isoforms. But these 





Figure 5-12. The Amplification factors of 1H on Cb of Cys of STD-NMR spectra 
The mapping of ligand binding moieties of cysteine is shown in Figure 5-13. The 
amplification factor of hydrogen on Cb of alanine is lower than that of hydrogen on Ca 
in all four isoform assays.  This result might suggest that alanine binds to the same 
pocket of four isoforms. 
 
 
Figure 5-13. The mapping of ligand binding moieties of alanine in the STD-NMR 
spectra of all four human PYK isoforms with cysteine. H(A)-H(B) represent hydrogens 
on the Calpha and Cbeta carbon atoms of Cys. 
5.2.4 STD-NMR results for M2PYK with increasing L-alanine concentration 
To study the dissociation constant (Kd) of L-alanine binding with M2PYK, we carried 
out a series of STD-NMR assays with increasing alanine concentration from 111 nM 
to 3 mM. Spectra for off-resonance 1H NMR data of four isoforms with alanine are 
















different groups of peaks in each spectrum: water signals at 4.7 ppm, alanine signals 
at 3.7 ppm and 1.4 ppm, and contamination signals at about 3.5 ppm and 1.1 ppm. If 
we compare the magnitudes of peaks at the same position in the four spectra, we can 
easily see that the water and contamination signals remain at the same respective levels, 
but alanine signals increase with alanine concentration. 
 
Figure 5-14. Stacked spectra of off-resonance NMR data of M2PYK with four L-
alanine concentrations (0.11 mM_purple, 0.33 mM_green, 1mM_red, and 3mM_blue) 
confirming that signal magnitude of the alanine peaks increases with alanine 
concentration.   Water signals are shown with blue arrow, alanine signals with yellow 
arrows, and contamination peaks with orange arrows. 
The STD-NMR results in Figure 5-15 show that peaks at 3.7 ppm and 1.4 ppm are 
related to the alanine concentration (higher alanine concentrations show higher signals) 
confirming that the concentration of the M2PYK-alanine complex increases with the 
alanine concentration.  
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Figure 5-15. Comparison of peak intensities in the STD-NMR spectra of alanine with 
human pyruvate kinase M2 with four different alanine concentrations. 
The STD amplification factor at 1.4 ppm for four spectra were calculated and plotted 




 Equation 5-3  
Figure 5-16 shows that amplification factor maximum is 0.4 and the estimated Kd is 
231 µM. According to the previously determined enzyme assay data, Kd[Ala] is 62 
µM, which is about 4 times smaller than calculated from the STD-NMR results. The 







Figure 5-16. The alanine binding effect on M2PYK was detected by STD-NMR. STD 





















































K d = 2 3 1 μM
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CHAPTER 6. SAXS studies on hPYKs 
Attempts to crystallise full length hRPYK and hLPYK were unsuccessful. SAXS 
(Small-angle X-ray scattering) provides a way of obtaining protein structural 
information in solution rather than in a crystal (Dyer et al., 2014; Skou, Gillilan, & 
Ando, 2014).  
As shown in Figure 6-1, an incident X-ray beam penetrates the protein 
solution/background solution and scatters on a 2D detector from which structural data 
can be derived. Unlike X-ray crystallography, the protein molecules in solution are 
randomly oriented and undergo Brownian motion, so the scattering pattern is an 
average over all orientations. The scattering vector is defined as q = (4psinq) / l, where 
2q is the angle between incident X-ray and scattered X-ray, l is the wavelength of the 
incident X-ray radiation. The 2D scattering image can be integrated into a 1D curve 
(the intensity plot in Figure 6-1), after a subtraction of buffer scattering intensity from 
protein sample scattering intensity, defined as scattering intensity / versus q with a unit 
of inverse angstroms. The curve of log[I(q)]/q reveals information about oligomeric 
state, shape, and size of the sample protein. The Fourier transform of the curve 




Figure 6-1. Schematic representation of SAXS experiment with protein in solution. 
The incident X-rays penetrate the protein solution and scatter at a low angle. A 2D 
detector is used to capture the scattered photons. The angle between incident beam 
and scattered photons is 2q (generally <3° ), q is the scattering vector, describing the 
change of scattered radiation. The upper part of the intensity plot is the log[I(q)]/q 
curve, where I(q) represents the scattering intensity. After the Fourier transform, the 
P(r) function is constrained between r = 0 and r = dmax. 
 
More information such as I(0) (the zero angle scattered intensity when 2q = 0) and Rg 
(radius of gyration) can also  calculated (Jacques and Trewhella, 2010). As the I(0) cannot 
be distinguished from the unscattered radiation beam, we can calculate the value of 
I(0) by two methods.  
One is the Guinier analysis when q is small:  
Equation 4 
165 
Using this equation a linear fit of ln[(I)q] versus q can be used to calculate I(0) and Rg, 
when qRg < 1.3 Å (Jacques and Trewhella, 2010). A downturn or an upturn indicates 
interparticle interference or aggregation respectively when q is low (Mertens and 
Svergun, 2010). 
The other calculation of Rg and I(0) is more accurate using the entire scattering profile 
with P(r) distribution function: 
Rg is the second moment of P(r). 
Equation 5 
I(0) is the zeroth moment of P(r) 
Equation 6 
Molecular weight can also be calculated through extrapolation of the relationship of 
I(0) and the particle volume. 
Equation 7 
 
Where N is the number of scattering particles per unit volume, V is the particle volume, 
Dr is the contrast (the difference between the electron densities of the buffer and 
protein molecule), C is the mass per unit volume, u is the partial specific volume, MW 
is the molecular weight, NA is the Avogadro’s number (Jacques & Trewhella, 2010). 
SAXS experiments were carried out at the Diamond Light Source, Oxofordshire, UK 
at the B21 BioSAXS beamline. All samples were dissolved in PBS-CM buffer (9.33 
mM potassium phosphate, 136 mM, NaCl, 2.7 mM, KCl, 0.6 mM, MgCl2, 0.9 mM 
CaCl2). The data were obtained at room temperature (25 °C). To check concentration 
dependant effects and amino acid binding effects on the protein structure, we used a 
series of protein concentrations in SAXS experiments: 
1) For M1PYK: 0.87, 1.74, 3.48, 6.97 mg/ml 
2) For M2PYK: 0.25, 0.5, 2.3 mg/ml 
166 
3) For LPYK: 1.39, 2.78, 5.55 mg/ml 
4) For RPYK: 3.2 mg/ml 
5) For M2PYK with 2.5 mM Phe: 0.25, 0.5, 1, 2.3 mg/ml 
6) For M2PYK with 2.5 mM Ser: 0.25, 0.5, 1, 2.3 mg/ml 
The data were analysed through Scatter 3.0H. 
6.1.1 SAXS analysis of human M1PYK 
SAXS data was generated from His-tagged human M1PYK at a series of 
concentrations.  Guinier analysis of the data was used to determine parameters 
including Rg, Porod volume mass, P(r) Rg, and Dmax (as described above) which are 
presented in Error! Reference source not found.. The Guinier analysis mass 
(between 215.24 kDa to 238.21 kDa) and Rg (between 44.0 to 45.3) remain constant 
as the protein concentration increases. The mass of M1PYK is 240.4 kDa which is in 
the range. If the I(0)/c or Rg increases with concentration, there might be concentration 
dependant protein aggregation or oligomeric state change. The lack of such a 
correlation suggests that there is no concentration dependant oligomerisation (or 
aggregation). The molecular weight (between 251.85 and 271.59 kDa) calculated from 
Porod volume (non-concentration dependant) is slightly higher than the Guinier 
analysis mass (from 215.24 to 238.21 kDa). The average calculated Dmax is about 108.5 























0.87(14.45µM) 238.21 45.3 259.68 40.01 109 Tetramer 
1.74(28.9µM) 221.20 44.8 271.59 37.16 110 Tetramer 
3.48(57.8µM) 215.24 44.3 265.65 39.26 108 Tetramer 
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6.97(115.6µM) 219.32 44.0 251.85 40.10 107 Tetramer 
Average 223.49 44.6 262.19 39.13 108.5  
Standard deviation 10.12 0.57 8.44 1.37 1.29  
Table 10. SAXS parameters of human M1PYK at a series of protein concentrations 
(0.87 – 6.97 mg/ml). The Rg of M1PYK is calculated to be 44.6 Å and 39.13 Å from 
Guinier analysis and real space analysis, respectively. From the estimated molecular 
weight of both analysis, the predicted assembly of the protein is tetramer.  
The two plots in Figure 6-2A suggests that M1PYK at 0.87 mg/ml is not aggregated: 
the intensity plot of M1PYK does not show a sharp drop in intensity at low q; Guinier 
fitting shows a linear plot without up or downturns in Figure 6-2 B. The q x Rg ranges 
from 0.35 to 1.27 and an Rg of 45.3 Å was estimated. The P(r) distribution was 
calculated using a q ranging from 0 to 0.14 Å  showing that DMAX is about 96 Å. 
 
A                                                           B 
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C                                                           D 
Figure 6-2. SAXS scattering data of M1PYK at 0.87 mg/ml.  
A intensity plot of M1PYK at 0.87 mg/ml.  
B Guinier fitting of the intensity plot from A. The q x Rg ranges from 0.35 to 1.27. A 
Rg of 45.3 Å was estimated.  
C P(r) distribution provides information including Rg, real space I(0), maximum 
dimension of particle, Dmax. Multiple shoulders appearing after 60 Å indicate multiple 
domains in the protein. 
D The estimated curve form P(r) fits well at q range from 0 to 0.14 Å-1. 
6.1.2 SAXS analysis of human M2PYK 
SAXS data were generated from His-tagged human M2PYK at a series of 
concentrations from 0.5 to 2.3 mg/ml with/without amino acids regulators (2.5 mM 
Phe or 2.5 mM Ser), to investigate how natural activators phenylalanine and serine 
affect the structural status of M2PYK. Guinier analysis mass, Rg, Porod volume mass, 
P(r) Rg, and Dmax are shown in Error! Reference source not found.. The Guinier 
analysis mass and Rg increase from 199.56 kDa to 712.04 kDa and from 41.3 to 43.7 
as the protein concentration decreases. It is much higher than the real protein molecular 
weight of 240.9 kDa. But the estimated protein Mw from Porod volume data increases 
along the concentration changes, indicative of oa significant concentration dependant 
protein aggregation or oligomeric state change for M2PYK. According to the 
analytical gel filtration data in Chapter 3.4.7, 50% of M2PYK molecules in solution 
dissociates at 0.1 mg/ml. The Mw overestimation might be created by a concentration 
dependant protein aggregation. At 2.3 mg/ml M2PYK, Guinier analysis mass of M2 
with Phe or Ser are 298.00 and 294.13 kDa, which is much higher than M2 alone 
(199.52 kDa). As protein was diluted to 1 mg/ml and 0.5 mg/ml, Guinier analysis mass 





concentrations Guinier Guinier Porod P(r) Dmax Oligomerisation 
(mg/ml) Analysis analysis volume Mass Rg (Å) state 
		 Mass Rg (Å)  (Å) 		 		
		  		 		 		 		 		
2.3 
(38.3µM) 199.52 43.7 259.68 40.57 101 Tetramer 
2.3(38.3µM) 
with Phe 298 44.4 274.04 31.46 111 Tetramer 
2.3(38.3µM) 
with Ser 294.13 43.5 253.82 41.4 110 Tetramer 
1.0(16.6µM) 712.04 42.2 413.39 39.89 105 - 
1.0(16.6µM) 
with Phe 658.75 41.8 421.41 39.32 104 - 
1.0(16.6µM) 
with Ser 725.36 42.1 407.73 39.67 107 - 
0.5(8.3µM) 642.46 41.3 370.67 35.35 83 - 
0.5(8.3µM) 
with Phe 676.27 42.3 
338.67 35.54 85 - 
0.5(8.3µM) 
with Ser 648.38 40.3 360.42 36.42 92 - 
Average 539.43 42.40 344.43 37.74 99.78   
Standard 
deviation 210.30 1.28 67.09 3.24 10.54   
 
Table 11. SAXS parameters of human M2PYK at a series of protein concentrations 
(0.5 – 2.3 mg/ml). The Rg of M2PYK is calculated to be 42.4 Å and 37.74 Å from 
Guinier analysis and real space analysis, respectively. Dmax is estimated to be 99.78 Å 
on average. Mass values from both analysis are with high standard deviations. 
Two figures in Figure 6-3 suggest that M2PYK at 2.3 mg/ml shows no aggregation: 
M1PYK has no sharp drop close to zero in Figure 6-3 A, Guinier fitting shows a linear 
plot without up or downturns in Figure 6-3 B.  The q x Rg ranges from 0.23 to 1.29. A 
Rg of 43.7 was estimated. The P(r) distribution was calculated using a q ranging from 




A                                                           B 
 
C                                                           D 
 
E                                                           F 
 
Figure 6-3. SAXS scattering data of M2PYK at 2.3 mg/ml. 
A intensity plot.  
171 
B Guinier fitting of the intensity plot from A. The q x Rg ranges from 0.23 to 1.29. A 
Rg of 43.7 was estimated.  
C P(r) distribution provides information including Rg , real space I(0), maximum 
dimension of particle, Dmax. 
D The estimated curve form P(r) fits well at q range from 0 to 0.14 Å-1. 
E P(r) distribution of M2PYK (green), M2PYK with 2.5 mM (purple), M2PYK with 
2.5 mM Ser (blue) almost overlap each other. Value of Rg, and maximum dimension 
of particle, Dmax for each are at same level. 
F The estimated curves of M2PYK (green), M2PYK with 2.5 mM (purple), M2PYK 
with 2.5 mM Ser (blue) form P(r) fits well at q range from 0 to 0.14 Å. 
6.1.3 SAXS analysis of human LPYK 
SAXS data were generated from His-tagged human LPYK at a series of concentrations 
from 1.39 to 5.55 mg/ml.  Guinier analysis mass, Rg, Porod volume mass, P(r) Rg, and 
Dmax are shown in  . The Guinier analysis mass (between 204.48 kDa to 215.51 kDa) 
and Rg (between 42.6 to 43.1) remain constant as the protein concentration increases. 
It is close to the real protein molecular weight of 242.7 kDa. The estimated protein 
Mw or Rg are stable as the concentration changes and it seems that there is not a 
concentration dependant protein aggregation or oligomeric state change for LPYK. A 
molecular weight (from 245.1 to 255.96 kDa) calculated from Porod volume (non-
concentration dependant) is slightly higher than the mass calculated from the Guinier 
analysis. Dmax is determined by the points from 0 to 0.15 Å as there is high noise ratio 
























215.51 43.1 255.96 40.47 116 Tetramer 
2.78 
(45.73µM) 
206.7 42.6 248.54 39.87 118 Tetramer 
1.39 
(22.86µM) 
204.48 42.6 245.10 39.89 121 Tetramer 
Average 208.90 42.77 249.87 40.08 118.33   
Standard 
deviation 5.83 0.29 5.55 0.34 2.52 
  
 Table 12. SAXS parameters of human LPYK at a series of protein concentrations 
(1.39 – 5.55 mg/ml). The Rg of LPYK is calculated to be 42.77 Å and 40.08 Å from 
Guinier analysis and real space analysis, respectively. Dmax is estimated to be 118.33 
Å on average. 
Two figures show that LPYK at 1.39 mg/ml is not aggregated: the intensity plot has 
no sharp drop close to zero in Figure 6-4 A, Guinier fitting shows a linear plot without 
up or downturns in Figure 6-4B.  The q x Rg ranges from 0.17 to 1.27. A Rg of 42.8 
was estimated. The P() distribution was calculated using a q ranging from 0 to 0.12 Å. 
 




C                                                           D 
 
Figure 6-4. SAXS scattering data of LPYK at 1.39 mg/ml. 
A intensity plot.  
B Guinier fitting of the intensity plot from A. The q x Rg ranges from 0.17 to 1.27. A 
Rg of 42.6 was estimated.  
C P(r) distribution provides information including Rg, real space I(0), maximum 
dimension of particle, Dmax. Dmax is about 115 Å. 
D The estimated curve form P(r) fits well at q range from 0 to 0.12 Å-1. 
6.1.4 SAXS analysis of human RPYK 
SAXS data were generated from His-tagged human RPYK at 3.2 mg/ml.  Guinier 
analysis mass, Rg, Porod volume mass, and Dmax are shown in Error! Reference 
source not found..  Molecular weight (259.68 kDa) calculated from Porod volume 
(non-concentration dependant) is slightly higher than the Guinier analysis mass 
(223kDa) and is close to the calculated protein molecular weight of 256.0 kDa. Dmax 
is 144 Å and determined by the points from 0 to 0.12 Å as there is high noise ratio for 
higher q. It is much higher than Dmax of other isoforms (M1: 108.5 Å, M2: 99.78 Å, L 
118.33 Å). Compared to the LPYK sequence in Chapter 1.1.1, RPYK has a N-terminal 

























223.16 51 259.68 47.53 144 Tetramer 
Table 13. SAXS parameters of human RPYK at 3.2 mg/ml. The Rg of RPYK is 
calculated to be 51 Å  and 47.53 Å from Guinier analysis and real space analysis 
respectively. Dmax is estimated to be 144 Å. 
 
A                                                           B 
 
C                                                           D 
Figure 6-5. SAXS scattering data of RPYK at 3.2 mg/ml. 
A. intensity plot.  
B. Guinier fitting of the intensity plot from A. The q x Rg ranges from 0.12 to 
1.07. A Rg of 51 was estimated.  
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C. P(r) distribution provides information including Rg, real space I(0), maximum 
dimension of particle, Dmax. 
D. The estimated curve for P(r) fits well at q range from 0 to 0.12 Å-1. 
6.1.5 Discussion 
The major aim of the SAXS experiments was to obtain structural insights of the four 
His-tagged human pyruvate kinases. Data were collected for each protein over a range 
of protein concentrations. From the results of the whole set of STD-NMR data, apart 
from M2PYK at low protein concentrations (1.0, 0.5 mg/ml), the molecular weight 
data based on Guinier analysis are similar to the theoretical tetrameric PYK molecular 
weights. The mass predictions of all four isoforms using P(r) distribution are also in 
agreement with calculated values but slightly higher than Guinier analysis data. Taken 
together, these data would suggest that human pyruvate kinases are tetrameric in 









CHAPTER 7. Summary and forward look 
This thesis has discussed biochemical and biophysical studies of all four human 
pyruvate kinase forms (M1PYK, M2PYK, LPYK, and RPYK) and provides a number 
of novel and interesting insights. Firstly, reducing environments were found to play an 
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important role in enzyme activity regulation, thermal stability, and oligomerisation 
states. Secondly, selected amino acids were identified as inhibitors or activators of 
enzyme activity. Thirdly, biophysical assays (STD-NMR and SAXS) were used to 
obtain new information about the interactions of human pyruvate kinases and free 
amino acids. 
7.1 Summary of thesis 
The biology and biochemistry of the four human pyruvate kinases were reviewed and 
the hypothesis was developed that regulation of the PYK isoforms was a result of the 
different biochemical environments of the various human cell types. (CHAPTER 1) 
Four human pyruvate kinase isoforms (M1PYK, M2PYK, LPYK, and RPYK) were 
produced in stable and robust E. coli culture systems. The protein purification 
protocols were shown to be reproducible. Kinetic and biophysical properties of these 
proteins were characterised. (CHAPTER 2) 
The analytical gel filtration assay shows that only M2PYK exists in an equilibrium 
between tetramers and monomers at 0.1 mg/ml, while the other three isoforms were 
only observed as tetramers. We also found that enzyme activity drops significantly 
after dilution to a low concentration (0.001mg/ml). M2PYK activity loss could be 
explained by monomerisation. However, the loss of activity for LPYK and RPYK 
might be due to another process such as oxidation. We also proved that reducing 
reagents prevent the loss of activity. (CHAPTER 3) 
We identified some amino acid regulators of human pyruvate kinases, some being 
activators and some inhibitors. Each regulator can activate or inhibit one or more 
isoforms. For M2PYK, we also found that both inhibitor and activator amino acids are 
competitive.  Certain amino acids like alanine, which neither inhibit nor activate 
M2PYK were also found to compete with other amino acid regulators.  (CHAPTER 4) 
STD-NMR data suggested that all amino acids have a universal binding mode with all 
human pyruvate kinase isoforms.  (CHAPTER 5) 
SAX study showed that hPYKs are tetrameric in solution.  (CHAPTER 6) 
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7.2 Discussion 
7.2.1 Cysteine oxidation regulation on hPYKs 
According to the redox regulation tests on hPYKs, three of these (M2PYK, RPYK, 
and LPYK) are sensitive to the reducing reagent DTT. Moreover, RPYK lost its 
activity during long periods of incubation, while DTT could maintain activity from the 
beginning or even partially recover its activity. In the analytical gel-filtration assays, 
reducing reagent helped wild-type M2PYK to maintain a majority in tetrameric 
oligomeric states after 12 hours of incubation at 0.1 mg/ml protein concentration (in 
Dr Meng Yuan’s thesis). However, RPYK and LPYK didn’t show any dissociation 
from tetramers to monomers during the long incubation period as demonstrated by 
results in Chapter 3. Based on the sequence comparison in Chapter 1.1.2, we know 
both 358 and 326 residues of M2PYK are conserved at the same position of the other 
isoforms. 
All these results suggest that RPYK and LPYK might be regulated by redox regulators 
via oxidation or reduction on cysteines present on the surface of the protein, just like 
in M2PYK but without dissociation. Anastasiou et al. demonstrated that the redox state 
regulates M2PYK enzymatic activity and oligomerisation state, and also suggested 
that Cys358 was the major residue in the structure to be oxidized (Anastasiou et al., 
2011). In 2014, Dr Rosie Mitchell demonstrated that Cys326 could be regulated by 
redox state in her PhD thesis. Dr Meng Yuan also showed in his PhD thesis that Cys326 
positions in the tetramer interface of M2PYK and a mutant, M2PYK-C326S (cysteine 
to serine), changes the M2PYK to monomeric form and with very low activity. The 
sequence and structure differences in the C-C interface of M1PYK and M2PYK might 
explain this phenomenon, as shown in Figure 7-1 (from Dr Meng Yuan’s unpublished 
work). It is shown that the salt bond between residues Arg399 and Glu418 within the 
same subunit in a T-state tetramer changes to a new salt bond between Arg399 in one 
subunit and Glu418 in the adjacent subunit. But in the M1PYK structure, the 399 
position is valine which cannot form the salt bond but remains close to maintain the 
R-state. According to the sequence information, the 399 position in RPYK and LPYK 
is identical to M2PYK. This might explain why RPYK and LPYK could be regulated 
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from T-state to R-state by the Arg399-Glu418 salt bond leading conformational 
change. 
 
Figure 7-1. C-C interface of M2PYK, R-state and M1PYK R-state.   
Future work to explore the function of C358 and other cysteine residues in LPYK and 
RPYK could involve the design of mutated proteins where the respective cysteine 
positions are replaced by stable residues like serine and to investigate their enzymatic 
activity and the structure change. 
7.2.2 Metabolites binding and regulation in hPYKs 
Among the metabolites we tested, there were a group of activators, inhibitors, and non-
regulators detected, the results are summarized as follow: 
For M1PYK, only Phe inhibits its enzymatic activity slightly by 14%, this was also 
shown in previous studies (Rozengurt, de Asúa, & Carminatti, 1970). Ala has been 
reported to have an inhibition effect on M1PYK (Williams, Holyoak, McDonald, Gui, 
& Fenton, 2006), however in this study we failed to demonstrate significant regulation 
of M1PYK. F-1,6-BP, the natural effector of the other three isoforms, didn’t show any 
activation effect on M1PYK, which is consistent with previous literature (Jurica et al., 
1998). Oxalic acid, an analogue of the substrate, inhibits M1PYK strongly by 75% 
confirming the previous report (Buc HA, 1981). Other amino acids and metabolites 
tested didn’t show any enzymatic regulation of M1PYK. 
For M2PYK enzymatic tests, F-1,6-BP, Ser, His and Gly showed a strong activation 
effect on enzyme activity. Oxalic acid, GMP, AMP and a group of amino acids (Tyr, 
Met, Val, Iso, Phe, Ala, Pro, Thr) were identified as strong inhibitors. This confirmed 
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the relative reports in literature: Cys and Phe were reported to have inhibitory effect 
on M2PYK (H. P. Morgan et al., 2013; Nakatsu et al., 2015), while Cys was reported 
to be an activator (Chaneton et al., 2012). 
For LPYK, F-1,6-BP as effector and oxalic acid show an activation and inhibition 
effect, respectively. No regulatory effect of Ala on LPYK was detected during tests 
here, which is inconsistent with the published inhibition effect (Llorente, Marco, & 
Sols, 1970). All other metabolites are non-regulators for LPYK. 
For RPYK, F-1,6-BP as effector and oxalic acid still show a strong activation and 
inhibition effect, respectively. Eleven amino acids and alpha-ketoglutarate were 
detected as activators for RPYK. Ala was reported as inhibitor in an early report (Marie, 
Buc, Simon, & Kahn, 1980), however in our study Ala is shown to be an activator. 
Surprisingly, the STD-NMR study of hPYKs (M1PYK, M2PYK, LPYK, RPYK) with 
amino acids (His, Phe, Ala, Ser, Cys) in Figure 5-5 showed that each of the 1D protein 
NMR spectra of protein-ligand combinations we have tested gave binding signals, this 
includes the protein isoforms with both their regulators and non-regulators from the 
metabolite list we tested in activity assays as shown in Error! Reference source not 
found..  For example, Ala is an activator for RPYK, an inhibitor for M2PYK, and a 
non-regulator for M1PYK and LPYK. Although the biological and structural 
properties are different, this phenomenon suggests that there might be universal 
binding between amino acids and hPYKs. A conserved binding pocket for all amino 
acids is possible.  
Based on my colleague Dr Meng Yuan’s work on the human M2PYK crystal structures,  
human M2PYK co-crystallized with alanine, phenylalanine, serine and tryptophan 
without F-1,6-BP, shows that all four amino acids regulate the activity of M2PYK by 
stabilising the tetrameric structure in T or R state, shown in Figure 7-2. The 
hydrophobic amino acids (Ala, Phe, Trp) stabilise the M2PYK tetramer as T state and 
the hydrophilic amino acid stabilises the R state. The conformational transformation 
between two states is facilitated by a rigid-body rotation of 11° of each subunit.  
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Figure 7-2. M2PYK tetramers equilibrate between R and T state. The active R state 
tetramer and the inactive T state tetramer are indicated by green and purple, 
respectively. The rotation direction is shown by arrows. The figure is provided by Dr 
Meng Yuan’s unpublished work. 
Furthermore, the binding pockets identified in these structures are identical, as shown 
in Figure 7-3. The same allosteric binding pocket is located between the A-domain and 
C-domain of each subunit of the tetramer. The binding locations of each amino acid is 
in the same direction. The carboxyl groups of the four amino acids are bound to the 
residues Asn70 and Arg106, and their amino groups to residues His464 and Ile469. In 
addition, the hydroxyl group of serine forms a hydrogen bond with Arg43 located on 
the N-terminal part, while other amino acids push the N-terminus away by 
approximately 6 Å, and thereby trigger the conformational transformation from the R 
to the T state. 
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Figure 7-3. The binding of amino acids (Phe, Ala, Trp, Ser). (A) the architecture of 
one subunit of M2PYK. (B-E) structure of the amino acid binding site with four 
amino acids, respectively. The figure is provided by Dr Meng Yuan’s unpublished 
work. 
Compared with the structure from early reports shown in Figure 1-6, the amino acid 
binding pocket identified in M2PYK is similar in the other PYK isoforms and the 
residues involved in ligand binding are identical. On the basis of the STD-NMR study 
and Dr Meng Yuan’s structure information, we could hypothesize that the amino acid 
pockets in all four PYK isoforms are conserved and might bind any amino acid. But 
the effect of the binding on the protein structure can change depending on the amino 
group interaction with the residues in the N-terminal part. Therefore the hypothesis 
of amino acid binding and regulation is that the conserved amino acid pocket is highly 
receptive to the binding of amino acids but the consequent new bond formation at the 
C-C interface and conformational change is more important in maintaining the 
oligomeric state. This also explains why one amino acids’ (alanine as inhibitor) 
regulatory effect on M2PYK is changed by the presence of another amino acid (serine 
as activator).  
There are many interesting aspects around the topic of the regulatory effects of 
metabolites on hPYKs which could be studied in future work. For example, the effect 
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of combinations of two activators (for example: serine and alanine with RPYK), one 
activator/inhibitor with one non-regulator (for example, serine with tyrosine on 
M2PYK) has not yet been studied. Because there are many amino acids and other 
metabolites present in cytosol, it is the combination effect of all regulators and non-
regulators (they might also occupy the amino acid pocket) that will determine the 
enzymatic activity rather than any single amino acid. Secondly, the combination of 
amino acids (use phenylalanine as example) with the potent allosteric activator F-1,6-
BP, binding in a different effector site, has not been studied so far. Phenylalanine 
pushes the tetrameric equilibrium from R state to the T state while F-1,6-BP leads to 
the opposite effect. The result might be that at certain F-1,6-BP concentration, amino 
acids (use phenylalanine as example) can up-regulate RPYK and down-regulate 
M2PYK but at a higher level of F-1,6-BP phenylalanine may lose  its regulatory effects. 
Thirdly, attempts to generate crystal structures of RPYK co-crystalised with activators 
will be important to confirm the binding site and the mechanism of the regulations. 
Crystal structures of hPYKs with non-regulators will be useful to confirm if the 
universal binding exists.  
7.2.3 Oligomeric structure of the PYK isoforms 
Based on the study of analytical gel filtration, the oligomerisation states of M1PYK, 
RPYK, LPYK are predominantly tetramers in the PBS solution (also used in enzymatic 
tests) at low protein concentration (0.1 mg/ml). M2PYK solution contains both 
tetramers and monomers. The results of a related study by Dr Meng Yuan also 
suggested that M2PYK at certain protein concentration (0.1 mg/ml) equilibrates from 
tetramers to a mixture of monomer and tetramers. Here, we discuss the possible 
oligomeric states of each PYK isoform in the presence of different metabolites. 
Based on the evidence from Chapter 3 and Chapter 4, M1PYK is always fully activated 
and was not regulated by the reducing reagent DTT, any of the metabolites listed in 
Table 9, or through long incubations at low concentration. The oligomeric state of 
M1PYK should be predominantly R-state tetramers in the presence of any ligand tested, 
reducing reagent, or at low concentration with long incubation time. The explanation 
to this phenomenon might be that M1PYK expressed in muscle cells with a constant 
high energy demand requires M1PYK’s full activity under any condition. Although 
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the muscle cells always contain high amino acid concentration and alanine was 
reported to have an inhibitory effect on M1PYK (McCormack et al., 2017), the 
universal binding hypothesis suggests that alanine inhibition won’t play an important 
role while in the presence of all other non-regulator binding amino acids. 
For M2PYK, there might be three situations. It was shown that the protein is in R-state 
tetramers in the presence of F-1,6-BP, or other identified activators (Chapter 4) and in 
the presence of reducing reagent (Chapter 3). It is present as T-state tetramers in the 
presence of metabolites identified as inhibitors. It could also be seen to exist as 
monomers in the presence of T3 or at low protein concentration for a long incubation 
time.  
For RPYK and LPYK, the oligomeric state of the protein is generally tetrameric. 
Activators and inhibitors push the equilibrium to one of R state and T state, 
respectively. Non-regulators might not lead to any conformational change. 
7.2.4 The structure and physicochemical properties of the metabolites analysis 
The amino acid regulation of PYKs might be related to their physiochemical properties 
such as hydrophobicity. In Figure 7-4, we demonstrated that a higher hydrophobicity 
value of the ligand has a higher inhibitory effect on M2PYK activity and strong 
activators have a low hydrophobicity value. As shown in Figure 1-6 and Figure 7-3, 
the amino acid pocket is conserved and the residues in the pocket at different isoforms 
are identical, but Phe with a high hydrophobicity pushes the N-terminus away and 
changes the conformational state of the tetramer, while serine with low hydrophobicity 
forms a hydrogen bond with Arg43 which has lowest hydrophobicity value in the table.  
The observed relationship between hydrophobicity and enzymatic regulation is limited 
however as it cannot be applied to amino acids such as Leu and Arg and for RPYK. 
To expand this hypothesis, crystal structure information of other ligands with M2PYK 
or RPYK will be useful. Another factor in this ligand binding and regulation 
mechanism might be the size of the amino acid. 
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Figure 7-4. The amino acids hydrophobicity values compared with M2PYK and 
RPYK activities. The activity data are from Table 9. The hydrophobicity data are 
from the web: 
(https://www.cgl.ucsf.edu/chimera/docs/UsersGuide/midas/hydrophob.html#dnote) 
 
7.2.5 Possible biological implications 
M1PYK: The fully activated state of M1PYK exposed to any amino acid suggests that 
any change in amino acid concentrations won’t affect its activity. The biological 
function of M1PYK is simple and always fully active. 
M2PYK: The enzymatic regulation of M2PYK detected in Chapter 4 is summarized 
in Figure 7-5. Interestingly, all activators come from upstream – or upstream branches 
- in the pathway (F-1,6-BP, serine, glycine) or from uptake from outside the cytosol 
(histidine). The inhibitors come from downstream branches of the pathway (alanine) 
or from nutrient supply as dietary essential amino acids (proline, threonine, methionine, 
tryptophan, phenylalanine). In 2012, Chaneton demonstrated that in cancer cells serine 
is a natural regulator and described a rheostat-like mechanism between M2PYK 
regulation and the serine biosynthesis. Glycine is also derived from the serine 
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biosynthesis pathway and has an activation effect on M2PYK. The rheostat-like 
mechanism might be upregulated by a combination effect of serine and glycine. In the 
alanine biosynthesis pathway, alanine transaminase catalyses pyruvate to alanine, and 
its activity is normally elevated in tumour cells (Chougule, Hussain, & Agarwal, 2008). 
This phenomenon might form another rheostat-like mechanism between alanine 
biosynthesis and M2PYK regulation in normal cells but be rewired in tumour cell to a 
high alanine biosynthesis and low PYK activity state. Moreover, the explanation of 
the inhibition by GMP (guanosine monophosphate) and AMP (adenosine 
monophosphate) might be that the high DNA and RNA biosynthesis rates in fast 
proliferating cells result in suppression of M2PYK activity.  
 
Figure 7-5. The regulation of M2PYK by metabolic amino acids in the cytosol. 
LPYK: The liver type PYK is less active compared with M1PYK and is not strongly 
regulated by any amino acid or metabolites with only F-1,6-BP having an activation 
effect. The major functions of hepatic cells in glucose related biological processes are: 
glycogenesis when there are high blood glucose levels, glycogenosis when blood 
levels are low, gluconeogenesis when there are low blood glucose level and hepatic 
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glycogen reserves become exhausted. The gluconeogenesis pathway and glycolysis 
pathway are combined in Figure 7-6. The steps from pyruvate to PEP and F-1,6-BP to 
F6P are separate in both pathways, involving distinct enzymes, so it might be feasible 
that no F-1,6-BP accumulation occurs in gluconeogenesis. This could explain why 
LPYK could only be activated by F-1,6-BP as its activity could only be useful when 
the carbon flux follows glycolysis to generate ATP. Activity would remain low when 
gluconeogenesis occurs with possibly no F-1,6-BP accumulation in the cytosol. 
 
Figure 7-6. Combination diagram of the pathways of glycolysis and gluconeogenesis. 
RPYK: RPYK normally has low activity levels and could be regulated by many amino 
acids and F-1,6-BP. This might be explained by the unique biological environment in 
erythrocytes. The uptake of amino acids by erythrocytes after intestinal absorption 
could elevate the activator concentrations including alanine (from 0.5-0.7 mM), 
histidine (from 0.08-0.15 mM), isoleucine (from 0.08-0.23 mM) with glutamine 
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maintaining higher concentration at 0.55 mM (Agli et al., 1998). Based on the results 
from Chapter Figure 4-17, the AC50 of alanine, histidine, isoleucine, glutamine is 
estimated to be 1.0 mM, 0.1mM, 1.0 mM, 10 mM. Only the AC50 of histidine fits into 
the erythrocyte amino acid concentration range. When erythrocytes absorb glucose or 
amino acids to reach a high intracellular concentration, RPYK is activated and 
generates more pyruvate, raising the ATP/ADP ratio. In other biological conditions, 
the enzyme activity remains low. Further work on amino acid regulation of RPYK 
activity and this regulatory effect on the biological function of erythrocytes might 
require further studies to test  the glycolysis rate at different amino acid concentrations 
in erythrocytes. 
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